The role of activins and their antagonists in human melanoma cell lines by Öztürk, Deniz
                              
 
  
 
 
 
 
 
 
 
 
DIPLOMARBEIT 
 
 
 
 
Titel der Diplomarbeit 
 
 
 
The Role of Activins and Their Antagonists 
in Human Melanoma Cell Lines 
 
 
 
 
 
angestrebter akademischer Grad 
 
Magister der Naturwissenschaften (Mag. rer.nat.) 
 
 
 
 
Verfasserin Deniz Öztürk 
Matrikel-Nummer: 0208952 
Studienrichtung /Studienzweig 
(lt. Studienblatt): 
A441- Genetik und Mikrobiologie / Genetik und 
Pathologie 
Betreuer: Ao. Univ. Prof. Dr. Wolfgang Mikulits 
 
Wien, im 
 
März, 2011 
 
 
 
 
 
 
    2 
 
 
 
 
 
 
 
 
 
 
 
Herewith, I declare that this diploma thesis was performed by 
me at the Medical University of Vienna, Department of 
Medicine-I, Institute of Cancer Research and that I did not 
utilize any other sources than those specified in the references. 
 
 
Practical Supervisor and First Assessor: 
Priv. Doz. Dr. Michael Grusch 
 
Second Assessor:  
Ao. Univ. Prof. Dr. Wolfgang Mikulits 
 
 
 
 
 
 
 
 
    3 
 
 
 
 
Acknowledgement 
 
I would like to thank all those who participated in making this piece of work a 
reality. Special thanks go to my supervisor Dr. Michael Grusch, who has 
supported, helped and encouraged me during my diploma thesis.  
I would like to thank my family for supporting me throughout all my studies at 
University and I am equally thankful to my darling who actively  
motivated me at all levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    4 
Abstract  
 
BACKGROUND: Activins are secreted dimeric polypeptides belonging to 
the TGF-β family of growth and differentiation factors. They have been 
shown to regulate cell growth, differentiation, migration and angiogenesis 
in multiple tissues and organs. Activins interact with various binding 
proteins which include antagonists in the extracellular space (follistatin 
and FLRG) and antagonistic co-receptors at the cell membrane (cripto). 
Deregulation of activin signals has been found in several tumor types and 
linked to the malignant growth of tumor cells.  
OBJECTIVES: The purpose of this study was to (1.) analyze the 
expression of activins and activin antagonists in melanoma cell lines, (2.) 
functionally characterize melanoma cell lines overexpressing follistatin and 
(3) investigate potential signaling mechanisms of activin beta E. 
METHODS: The expression levels of all four human activin subunits and 
antagonistic factors were investigated in a panel of human melanoma cell 
lines by quantitative RT-PCR. Three melanoma cell lines were transfected 
with follistatin and clones stably overexpressing follistatin (confirmed 
using enzyme-linked immunosorbent assay, ELISA) were analyzed with in 
vitro migration and proliferation assays. The effect of follistatin-mediated 
inhibition of activin activity on tumour growth was also investigated by 
xenotransplantation experiments in SCID mice. The impact of activin E, 
activin A and follistatin on smad signaling was assessed by 
immunoblotting.  
RESULTS: Elevated expression levels of activin beta C (83%) were found 
in malignant melanoma cell lines compared to primary melanocytes. The 
expression of activin beta B (75%) and activin beta E (92%) in contrast, 
was downregulated, whereas activin beta A showed up- or down-
regulation depending on the cell line. Expression levels of follistatin (75%) 
and cripto (100%) showed upregulation. The other follistatin related 
proteins, FLRG and follistatin-like-1 were up- or down-regulated, 
depending on the cell line. Only one of the two isoforms of follistatin (Fst-
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315), encoding a 27 amino acid extension at the C-terminus, was found in 
nearly all melanoma cells, including primary melanocytes.  
Supernatants of follistatin overexpressing VM21 and VM1 cells contained 
more than 10-fold elevated levels of follistatin and were also confirmed to 
inhibit  smad phosphorylation induced by treatment with recombinant 
activin A. In vitro characterization of follistatin overexpressing cells 
revealed a tendency towards reduced proliferation but partly increased 
clonogenicity. Migration of melanoma cells was reduced ranging from 20% 
to 80% by overexpression of follistatin. Follistatin overexpressing VM21 
cells were also tested by a xenotransplantation experiment in SCID mice, 
but did not show a difference in tumor growth when compared to mock 
controls. 
Experiments with conditioned media showed that activin E, in contrast to 
activin A, does not lead to phosphorylation of smad2. Also no evidence 
was found that expression of activin beta E together with activin beta A 
could inhibit or enhance activin A-induced signals either by 
heterodimerization or by competition for activin receptors or follistatin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    6 
Zusammenfassung 
 
EINLEITUNG: Activine sind sezernierte dimere Polypeptide, die zur TGF-β 
Familie der Wachstums- und Differenzierungsfaktoren gehören. Activine 
regulieren Zellwachstum, Differenzierung, Migration und Angiogenese in 
verschiedenen Geweben und Organen. Die Funktion von Activinen wird 
seinerseits durch extrazelluläre Antagonisten (Follistatin und FLRG) und 
antagonistische Co-Rezeptoren an der Zellmembran (Cripto) limitiert. 
Deregulierung von Activin Signalen wurde in mehreren Tumorarten 
gefunden und in direkten Zusammenhang mit dem malignen Wachstum 
von Tumorzellen gebracht.  
ZIELE: Das Ziel dieser Studie war es, (1) die Expression von Aktivinen 
und Aktivinantagonisten in Melanomzellen zu untersuchen, (2.) den 
Einfluss von Follistatinüberexpression auf Melanomzellen zu testen und 
(3.) mögliche Signaltransdutionsmechanismen der Aktivin Beta E 
Untereinheit zu analysieren.  
METHODEN: Die Expression aller vier Aktivin Untereinheiten und 
antagonistischer Faktoren wurden in einer Reihe von humanen 
Melanomzellen durch quantitative RT-PCR untersucht. 3 Melanomzelllinien 
wurden stabil mit Follistatin transfiziert und die Überexpression wurde 
mittels ELISA bestätigt. Diese Zellen wurden dann in-vitro-in Migrations- 
und Proliferations-Assays getestet. Für Follistatin überexprimierende 
VM21 Zellen wurden auch Xenotransplantationsexperimente in SCID-
Mäusen durchgeführt. Die Auswirkungen von Activin E, Activin A und 
Follistatin auf den Smad Signalweg wurde mittels Western-Blot Analyse 
untersucht.  
ERGEBNISSE: Das Expressionsniveau von Activin C war in 
Melanomzelllinien erhöht  (83%) im Vergleich zu primären Melanozyten. 
Die Expressionniveaus von Activin beta B (75%) und Activin beta E (92%) 
dagegen reduziert, während Activin beta A unterschiedliche Regulation in 
Abhängigkeit von der Zelllinie zeigte. Expression von Follistatin (75%) und 
Cripto (100%) war erhöht. Die Expression der anderen dem Follistatin 
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verwandten Proteinen, FLRG und Follistatin-like-1 war je nach Zelllinie 
erhöht oder reduziert. Nur eine der beiden Isoformen von Follistatin (Fst-
315) wurde in nahezu allen Melanomzellen und in primäre Melanozyten 
gefunden.  
Überstände von stabil transfizierten Zellen enthielten mehr als 10-fach 
soviel Follistatin wie die Kontrollzellen. Überstände Follistatin 
exprimierender Zellen waren auch in der Lage Smad-Phosphorylierung 
durch zugegebenes Aktivin A zu neutralisieren. In-vitro, zeigten die 
Follistatin überexprimierenden Zellen eine Tendenz zu verminderter 
Proliferations, aber teils erhöhter Klonogenizität. Die Migrationsfähigkeit 
der Melanomzellen wurde um 20%-80% reduziert, wenn Follistatin 
überexprimiert wurde. Die Rolle der Follistatin vermittelten Hemmung des 
Activins wurde auch durch Xenotransplantation Experimente von VM21 
Zellen in SCID-Mäusen getestet. Allerdings war hier kein Unterschied im 
Tumorwachstum verglichen mit GFP-Kontrollen zu erkennen.  Bezüglich 
möglicher Signalwege von Activin E wurde nachgewiesen, dass durch 
Aktivin E konditionierte Medien im Gegensatz zu Aktivin A konditionierte 
Medien keine Smad2 Phosphorylierung aktiviert wird. Auswirkungen der 
Konditionierung von Medien mit unterschiedlichen Kombination von 
Activin E, Aktivin A und Follistatin liessen auch weder eine Blockierung 
noch eine Verstärkung von Aktivin A induzierten Signalen durch Aktivin 
beta E - wie etwa durch Ausbildung von AE Heterodimeren oder 
Konkurrenz um Aktivinrezeptoren oder Follistatinbindung - erkennen.   
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1. Introduction 
 
1.1. Cellular and Molecular Mechanisms of Melanoma 
Development and Progression 
 
1.1.1 Melanocyte Homeostasis and Melanomagenesis 
 
Melanoma develops from malignant transformation of melanocytes, which 
are pigmented, differentiated cells localized at different places of the 
human body, found  in the bottom layer of human epidermis (Uong and 
Zon), the inner ear (Markert and Silvers 1956), the middle layer of the 
eye (Barden and Levine 1983), meninges (Mintz 1971), heart (Theriault 
and Hurley 1970), and bones (Nichols and Reams 1960). Melanocytes are 
responsible for the production of melanin pigments and transporting to 
keratinocytes (Figure 1.1). Melanin is synthesized inside of melanosomes. 
Melanocytes develop from melanoblasts, which are derived from migratory 
neural crest cells. These cells are induced in gastrulation, in the area 
between the neural and non-neural ectoderm (Hirobe 1994; Erickson and 
Reedy 1998). 
 
Figure 1. 1 Schematic model of skin cells. 
The melanocytes are located in the basal 
layer, produce and secrete melanin to 
surrounding keratinocytes. (http:// health. 
howstuffworks. com/ skincare/ problems/ 
medical/ albinism1.htm. accessed on 
2010-12-07) 
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There is a relationship between melanocytes and keratinocytes, in which 
one melanocyte transports pigment containing melanosomes through its 
dendrites to about 36 associated keratinocytes (Fitzpatrick and 
Breathnach 1963; Jimbow, Quevedo et al. 1976). In this case, 
melanocytes are located in the basal layer of the epidermis, where they 
maintain a life-long stable ratio of 1:5 with basal keratinocytes (Haass and 
Herlyn 2005). Regulated induction of melanocyte division keeps this 
balance, and this ratio is only disturbed during transformation into a 
melanoma or a nevus. The expansion of the total skin surface during 
childhood requires melanocyte proliferation to maintain a stable ratio with 
the basal keratinocytes. In order to proliferate, melanocytes need to 
decouple from the keratinocytes and from the basement membrane, 
retract their dendrites, divide, and migrate along the basal layer of the 
membrane, before they finally recouple to the matrix and to keratinocytes 
to form another epidermal melanin component (Figure 1.2.) (Haass and 
Herlyn 2005). Cell division for melanocytes probably begins with the 
upregulation of growth factors which are produced by fibroblasts or by 
keratinocytes that leads to decoupling of melanocytes from keratinocytes 
and downregulation of cadherins. Mitogenesis is driven and regulated by 
other growth factors from epidermis or dermis.  
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Figure 1. 2 Steps of melanocyte proliferation in normal human skin and associated 
molecular events. For proliferation, melanocytes need to decouple from the basal layer of 
membrane and from the keratinocytes, retract their dendrites (Figure 1.3a), divide 
(Figure 1.3b), and migrate along the basal membrane (Figure 1.3c) before they finally 
recouple to keratinocytes and to the matrix to form another epidermal melanin unit 
(Figure 1.3d) (Haass and Herlyn 2005). 
 
 
Homeostasis physiologically determines whether a cell proliferates, 
differentiates, remains quiescent or undergoes apoptosis (Bissell and 
Radisky 2001). Imbalance of homeostasis may disturb the regulation of 
the epidermal melanin unit and stimulate continuous proliferation of the 
melanocytes, which may cause the development of melanoma. Hallmarks 
for melanoma cells include independence from exogenous growth factors 
through the production of autocrine growth factors or the constitutive 
activation of growth factor-related signaling cascades, unlimited life span, 
escape from control by keratinocytes, unresponsiveness to inhibitory 
growth factors such as transforming growth factor beta (TGF-β), invasion 
into the dermis, recruitment of fibroblasts for matrix and growth factor 
production, and recruitment of a neovasculature (Hanahan and Weinberg 
2000). It is likely that melanoma cells escape from control by 
keratinocytes through the following mechanisms: (1) downregulation of 
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receptors important for communication with keratinocytes, (2) 
upregulation of receptors and signaling molecules important for melanoma 
cell–melanoma cell and melanoma cell–fibroblast interactions, (3) 
deregulation of morphogens that directed them during development to the 
epidermis and helped maintain their proper position, (4) loss of anchorage 
to the basement membrane because of an altered expression of cell–
matrix adhesion molecules, and (5) increased production of 
metalloproteinases (Haass and Herlyn 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3 The effective factors during melanoma progression. At the 
cellular level, environmental, genetic and epigenetic alterations play a 
key role in epistatic changes. The model suggests that alterations in the 
expression of some specific proteins give rise to homeostatic imbalance in 
the skin and support melanoma progression. (Satyamoorthy and Herlyn 
2002) 
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Aberration between the normal melanocyte genome and genomes of 
melanoma cells has been clearly shown by genome analysis; this 
alteration can be categorized as environmental (UV radiation, sunburn), 
genetic (mutations, deletions, amplifications and translocations) and 
epigenetic (promoter hypermethylation), leading to epistatic changes 
(Figure 1.3). Experimental and epidemiological studies have indicated that 
strong exposures to UV radiation in early childhood may lead to melanoma 
in adults, but genetic and molecular studies have demonstrated additional 
autosomal abnormalities (Satyamoorthy and Herlyn 2002; Meyle and 
Guldberg 2009). 
 
It has become clear that several components in the skin influence 
homeostatic balance and tumour development. These include dermal 
fibroblast, epidermal keratinocytes, inflammatory and endothelial cells. 
The balance between keratinoctyes and these components keeps 
melanocytes from consistent proliferation.  
 
 
1.1.2. Cell–Cell Communication in Melanoma 
 
Expression of a number of cell surface molecules is acquired by 
melanocytes during progression to melanoma. These molecules allow 
melanocytes to survive, grow, adhere and migrate and they block some 
genes like E-cadherin, which is known as invasion suppressor and is 
expressed in the normal skin (Herlyn, Berking et al. 2000). Cadherins 
which are a family of cell surface glycoproteins play a key role in 
promoting Calcium-dependent cell adhesion. Besides, they promote 
intracellular communication and are a supplementary part of cell-cell 
adherens junctions (Steinberg and McNutt 1999; Vleminckx and Kemler 
1999). E-cadherin, expressed by keratinocytes and melanocytes, helps 
homophilic interaction and prevents melanocytes from aggressive cell 
division. On the other hand, expression of E-cadherin is progressively lost 
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during melanoma development, becomes heterogonous and gets 
distributed in the cytoplasm of the nevus cells, and is even predominantly 
absent in melanoma (Li and Herlyn 2000). It has been demonstrated that 
overexpression of E-cadherin in melanoma cells as well as co-culture with 
keratinocytes induces cell death and prevents growth, as well as invasion 
into the dermis (Hsu, Meier et al. 2000). In case of the loss of E-cadherin 
in melanoma cells, N-cadherin is expressed and this switching of the 
cadherin activity leads to tumor cell invasion, tumor-host cell interaction, 
migration as well as altered gene expression (Furukawa, Fujii et al. 1997) 
(Figure 1.3). N-cadherin is able to interact with fibroblast growth factor 
receptor (FGFR) to promote neurite formation and growth (Utton, Eickholt 
et al. 2001). The FGFR ligand FGF2 plays a significant role in promoting 
autocrine and paracrine growth effects in melanoma cells and inhibition of 
fibroblast growth factor receptor-1 (Becker, Lee et al. 1992; Wang and 
Becker 1997) leads to inhibition of tumor growth and cell death. In 
addition,  there are also some other molecules, which can be required for 
the homeostatic growth network. Alterations in melanoma include 
inhibition of supressor proteins such as Kiss1, NM23, and melastatin 
(Betke, Korabiowska et al. 1998; Deeds, Cronin et al. 2000), activation of 
matrix metalloproteinases and expression of cell-adhesion melocules such 
as αvß3 integrin, which increases with melanoma development from the 
radial to the vertical growth stage in primary melanoma and further to 
metatstasis (Hsu, Shih et al. 1998).  
 
As described above, melanoma cells express high levels of N-cadherin but 
have lost E-cadherin expression (Figure 1.4) (Haass and Herlyn 2005). 
The switching of cadherin profiles during melanoma progression enables 
melanoma cells to interact with other N-cadherin expressing cells such as 
fibroblasts, leading to tumor stroma adhesion, tumor cell migration and 
invasion as well as altered gene expression. It has been demonstrated 
that in melanma cells downregulation of E-cadherin is associated with gap 
junction incompatibility with keratinocytes (Hsu, Andl et al. 2000). 
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However changes in expression of gap junction molecules such as 
connexin 43 (Cx43)  may result in a reduction or the loss of GJIC, which 
plays a cooperative role in melanoma progression (Haass, Smalley et al. 
2004) and is able to regulate the growth, differentiation and migration of 
keratinocyte (Pitts, Finbow et al. 1988; Brissette, Kumar et al. 1994; 
Goliger and Paul 1995). It has been clearly demonstrated that all areas of 
melanomas are deficient in expression of gap junction molecules 
Cx26,Cx30 and Cx43. Suprisingly, Cx26 and Cx30 are induced in the 
epidermis of melanomas but they are not found in the epidermis of 
melanocytic nevi (Haass, Wladykowski et al. 2006).  
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Figure 1. 4 Cell–cell communication in melanoma.  E-cadherin, 
connexins and desmoglein 1 mediated interaction of normal 
epidermal melanocytes with keratinocytes (a). The cadherin 
profile can be changed from E- to N-cadherin during melanoma 
development, freeing the cells from epidermal keratinocytes as 
well as presenting new adhesive and communication 
characteristics. Besides melanoma cells have interaction with each 
other (b) with fibroblasts through N-cadherin, v 3 integrin/L1-
CAM, Mel-CAM/Mel-CAM ligand, ALCAM and connexins, (c) with 
endothelial cells through connexins and N-cadherin, and (d) 
through N-cadherin, v 3 integrin/L1-CAM, Mel-CAM/Mel-CAM 
ligand, 4 1 integrin/VCAM-1 and connexins (Haass and Herlyn 
2005). 
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1.1.3. Genetic Aberrations and Molecular Pathways in 
Melanoma Progression  
 
Despite strong exposure of melanocytes to environmental risk factors such 
as UV radiation and chemicals in the skin, melanomas do not only signify 
UV mediated mutations or aberrations. Mutations in the tumor suppressor 
gene p53 have been observed in less than 5% of melanoma patients. On 
the other hand,  mutations or deletions in the tumor suppressor p16INK4A 
have been found in more than 25%, whereas the mutations in the RAS 
oncogene have not exceeded more than 21% (Satyamoorthy and Herlyn 
2002). Besides, about 20-40% germ line mutations or deletions in 
chromosome 9p21 have been observed. This chromosome region includes 
cell-cycle inhibitors and tumor suppressors such as p15INK4B, p16INK4A and 
a differently coded locus of p16INK4A – p14/ARF (Sherr and Weber 2000). 
 
Although the majority of the mutations have been found in the p16INK4A 
locus, nearly 40% affect both p16INK4A and p14/ARF (Rizos, Puig et al. 
2001). The investigation for mutations or deletions in other genes such as 
PTEN, β-catenin, CDK4 did not yield significant occurrences of mutations 
in melanoma. Interestingly, despite its wild type status, p53  was shown 
to be functionally inactive in melanoma cells. (Satyamoorthy and Herlyn 
2002), (Satyamoorthy, Chehab et al. 2000). This indicates that activity of 
p53 is blocked either by post-transcriptional mechanism or other factors. 
It has been demonstrated that, melanoma cells overexpress the MDM2 
protein, which is implicated in inactivating p53 by targeting it for 
degradation (Rocco and Sidransky 2001). In addition, p53-dependent and 
independent apoptotic mechanisms can be inhibited by expression of the 
anti-apoptotic Bcl-2 protein (Hsu and Hsueh 2000). 
 
In melanoma cells also Apaf-1 (apoptotic protease activating factor-1) 
which initiates the protease cascade and activates caspase-9 has been 
shown to be inactivated through several ways, for example DNA 
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methylation (Soengas, Capodieci et al. 2001). Activation of caspase-9 is 
initiated by Apaf-1/cytochrome c and inactivated by serine/threonine 
kinase Akt/PKB signaling (Soengas, Alarcon et al. 1999; Zhou, Li et al. 
2000). Besides, bcl-2 is anti-apoptotic but is not absolutely cytoprotective 
against cell death by Apaf-1-caspase-9 signaling (Newmeyer, Bossy-
Wetzel et al. 2000). Akt-mediated caspase-9 phosphorylation leads to its 
reduced protease activity (Fujita, Jinbo et al. 1999).  It has been shown 
that several substrates of Akt/PKB play a role in cellular metabolism, cell 
survival and anti-apoptotic pathways.  
 
The MAPK pathway can be activated in melanoma cells in two ways, (1) 
production of autocrine growth factors HGF  and FGF (2) by BRAF gene 
mutation (Brose, Volpe et al. 2002). Inhibition of expression of autocrine 
HGF and FGF lead to downregulation of activation of ERK. This suggests 
that activation of members of the MAPK pathway is due to growth factors 
and genetic aberrations in distinct genes. Thus, there are multiple 
pathways involved in melanoma development. As presented in figures 1.5 
and 1.6, activation of STAT3 or of the PI3-kinase/Akt pathway, as well as 
NF-kB signaling indicates the involvement of a broad spectrum of 
endogenous or exogenous factors.  
 
 
 
 
 
 
 
Figure 1. 5 Relationship between mutations in Ras, BRAF and 
PTEN. Percentages of mutation in melanoma are indicated in 
parentheses. Flat line is for inhibition, arrow for activation 
(Haluska, Tsao et al. 2006).   
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BRAF and RAS are important molecules belonging to the MAPK signaling 
pathway. There are three highly conserved RAF gens: ARAF, BRAF and 
CRAF (Raf-1) (Emuss, Garnett et al. 2005; Zebisch, Staber et al. 2006) 
ARAF and Raf-1 mutations are rare in human malignant cells, although 
they are also capable to activate the MAPK pathway (Beeram, Patnaik et 
al. 2005; Palmieri, Capone et al. 2009).  Most mutations in the BRAF gene 
lead to a sigle substitution of valine with glutamic acid at amino acid 
position 600 (V600E) (Davies, Bignell et al. 2002). This mutation activates 
BRAF and leads to activation of the MEK-ERK signaling pathway in cells 
(Wan, Garnett et al. 2004). The activation of BRAF induces stimulation of 
downstream expression of the microphthalmia-accociated transcription 
factor (MITF) gen, which has been shown to play a role as the master 
regulator of melanocytes (Carreira, Goodall et al. 2005). It has been 
reported that there is a relationship between mutations in RAS, BRAF and 
PTEN. Concurrent BRAF-PTEN mutations function like NRAs mutation 
(Haluska, Tsao et al. 2006). NRAS mutations have been found in 10-20% 
of melanomas, loss of PTEN have been observed in 10-30% and c-KIT 
mutations seen in 23% of acral melanomas (Figure 1.5). The activating 
BRAF mutations have been observed in 60-80% of cutaneous melanoma 
tumors (Algazi, Soon et al. 2010). 
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Figure 1. 6 Pathways involved in melanoma. Pathway associated with N-RAS, BRAF, and 
mitogen-activated protein kinase (MAPK) as well as with CDKN2A and MITF are 
schematically represented. Arrows, activating signals, interrupted lines, inhibiting signals. 
BAD, BCL-2 antagonist of cell death; cAMP, cyclic AMP; CDK4, Cyclin-dependent kinase 
4; CDKN2A, Cyclindependent kinase inhibitor of kinase 2A; ERK1/2, Extracellular-related 
kinase 1 or 2; IkB, inhibitor of kB protein; IKK, inhibitorof- kB-protein kinase; MC1R, 
melanocortin-1-receptor; MITF, Microphthalmia-Associated Transcription Factor; MEK1/2, 
Mitogen-activated protein kinase-extracellular related kinase 1/2; PI3K, 
Phosphatidylinositol 3 kinase; PIP2, Phosphatidylinositol bisphosphate; PIP3, 
Phosphatidylinositol trisphosphate; PTEN, Phosphatase and tensin homologue    
(Palmieri, Capone et al. 2009). 
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1.2. Activins 
 
1.2.1. Introduction to Activins 
 
Another signaling system that is frequently deregulated in human 
malignancies is mediated via ligands of the the TGF-β family, their 
receptors and connected downstream effectors. The TGF-β family includes 
multiple factors that have not only tumor suppressor but also oncogenic 
effects (Piek and Roberts 2001). TGF-β, which is overexpressed in human 
melanoma cells, stimulates stroma cells to increase production and 
deposition of extracellular matrix proteins (Lopez-Bergami, Fitchman et al. 
2008). The activation of stroma contributes to increased metastasis and a 
tumor cell survival advantage (Berking, Takemoto et al. 2001). Melanoma 
cells are resistant to the tumor-suppressive effects of TGF-β. In contrast 
to other tumor types, however, no detectable defects are found at the 
TGF-β receptor or smad level in melanoma. On the other hand, inhibitors 
of the TGF-β family pathway such as follistatin, SKI, filamin and  endoglin 
can act as oncogens, because they interact with smad or membrane 
receptors by inhibition of tumor suppressive TGF-β signaling (Hussein 
2005; Reed, Lin et al. 2005). 
 
In normal physiology TGF-β has been shown to play a key role as a 
multifunctional polypeptide that regulates proliferation, differentiation, 
angiogenesis, embryonic development, wound healing and other functions 
in diverse cell types (Korpal and Kang 2010). The biological effects of TGF-
β are dependent on cell type, growth conditions, and the presence of 
other polypeptide growth factors (Jakowlew 2006). TGF-β is the 
eponymous member of a large superfamily of secreted proteins including 
activins, growth and differentiation factors (GDFs), bone morphogenetic 
proteins (BMPs), inhibins, nodal and anti-Mullerian hormone (Figure 1.7) 
(Korpal and Kang 2010). Like other members of this superfamily, inhibins 
and activins are multifunctional factors. They were first identified as 
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gonadal proteins and their names are based on their ability to inhibit or 
activate release of follicle-stimulating hormone (FSH) from the pituitary 
(Mayo 1994). In subsequent years, the bioactivities of activin were 
defined and were found to be exerted in various cell types at almost all 
stages of development. Furthermore, intracellular and extracellular 
proteins may regulate signaling and actions of activin (DePaolo, Bicsak et 
al. 1991). The extracellular activin binding-protein follistatin (Fst) is a 
monomeric secreted glycoprotein which binds activin with high affinity and 
blocks the ability of activin to adhere to its cell surface receptors (de 
Winter, ten Dijke et al. 1996). 
 
Figure 1. 7 Dendrogram of 35 structurally related members of the TGF-β superfamily. 
They are subdivided into TGF-βs, activins/inhibins, bone morphogenic proteins (BMPs)/ 
growth and differentiation factors (GDFs), and the related group of GDNF ligands 
(Weiskirchen, Meurer et al. 2009). 
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1.2.2. The Biology and Structure of Activin Subunits 
 
As members of the TGF-β family activins are secreted polypeptides 
(Schmierer and Hill 2007) They are homo- or heterodimers of two beta 
subunits each containing a cysteine knot fold with the monomers 
covalently linked by a single disulphide bond (Jhaveri, Erzurumlu et al. 
1998; Chen, Wang et al. 2006). Four different beta subunits exist in 
mammalian cells termed beta A, beta B, beta C and beta E. Homodimers 
are denoted by a single letter as activins A, B, C and E, whereas 
heterodimers by two letters according to their subunit composition (see 
Figure 1.8) (Tuuri, Eramaa et al. 1994). The activin beta A subunit is 
synthesized as a 426 amino acid (aa)  pro-protein (Deli, Kreidl et al. 
2008), containing an N-terminal 28 amino acid signal peptide followed by 
a pro-region (Mason, Niall et al. 1986). The C-terminal mature 116 aa 
polypeptide is enzymatically cleaved from the pro-region at an arginine 
rich processing site (Mason, Niall et al. 1986),(Schwall, Nikolics et al. 
1988). The pro-region of the activin beta A subunit plays a key role in the 
correct folding, secretion and dimerization of the activin protein (Gray and 
Mason 1990). All of the nine conserved cysteine residues in the mature 
part of the activin beta A subunit are required for the biosynthesis and 
biological activity of activin A (Mason 1994). The human activin beta A 
subunit gene is located on chromosome 7 locus 7p15-p14 (Barton, Yang-
Feng et al. 1989). In addition, human (Mason, Niall et al. 1986), porcine 
(Mason, Hayflick et al. 1985), bovine (Forage, Ring et al. 1986), rat (Esch, 
Shimasaki et al. 1987; Woodruff, Meunier et al. 1987) and mouse 
(Albano, Groome et al. 1993; Ritvos, Tuuri et al. 1995) activin beta A 
subunits are highly conserved and the mature parts of the proteins are 
identical between these species. 
 
The activin beta A and activin beta B subunits are the most widely 
expressed throughout the body and have high sequence homology 
(McDowall, Edwards et al. 2008). The beta B subunit of activin encodes a 
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precursor protein (407 aa) which contains a hydrophobic signal sequence 
as well as a pro-region of 292 aa separated from the mature C-terminal 
part (115 aa) by basic amino acids (Mason, Berkemeier et al. 1989). The 
activin beta B subunit lacks also putative glycosylation sites like the 
mature part of activin beta A. The human activin beta B subunit gene is 
localized on chromosome 2qcen-q13 (Barton, Yang-Feng et al. 1989) and 
consists of two exons separated by a 2.5 kb intron (Mason, Berkemeier et 
al. 1989). 
 
The activin C subunit is mostly expressed in the liver. The activin beta D 
subunit has only been found in Xenopus and the activin beta E subunit 
was isolated from mouse cDNA libraries but is present in all mammals. 
The activin beta E subunit shows close similarity to the activin beta C 
subunit in homology and expression patterns (McDowall, Edwards et al. 
2008).   
 
 
 
 
 
 
 
 
 
Figure 1. 8 Structural features of activin and inhibin. The mature activins 
(receptor binding active cytokine) are dimers consisting of two beta 
subunits joined by a disulphide bond, whereas inhibins are heterodimers 
of one alpha and one beta subunit. 
(http://en.wikipedia.org/wiki/Activin_and_inhibin, accessed on 2011-02-
08) 
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1.2.4. Activin Receptors and Activin Mediated Receptor 
Signaling 
 
The members of the TGF-β superfamily like activins A, B and AB exert 
their actions in signaling by interacting with two types of transmembrane 
receptors containing a serine/theronin kinase domain. For activin A it has 
been demonstrated that the signaling is started by ligand binding and 
activation of ActR-II (aka ACVR2) or ActR-IIB (aka ACVR2B). Type-II 
receptors activate the Type-I receptors ALK4 (aka ActR-IB / ACVR1B).  
(Wrana, Attisano et al. 1994; Vivien, Attisano et al. 1995; Vivien and 
Wrana 1995; Schmierer and Hill 2007). The activitated type-I receptor 
allows to phosphorylate intracellular smad proteins (McDowall, Edwards et 
al. 2008). There are three classes of smad proteins. Receptor regulated 
smads, known as R-smads, comprising smads1, 2, 3, 5 and 8; inhibitory 
smads (I-smads) are smad6 and smad7 and the last class of smads is the 
co-smad4 (McDowall, Edwards et al. 2008). smad2 and smad3 are 
phosphorylated by the receptors ALK4, ALK5, and ALK7, whereas smad1, 
smad5, and smad8 are phosphorylated by ALK1, ALK2, ALK3, and ALK6 
receptors. All R-smads bind to a smad4, allowing for nuclear translocation, 
where they regulate transcription of target genes, trough physical contact 
and functional cooperation with DNA-binding transcription factors and 
p300 or CBP co-activators (see Figure 1.9.) (Lagna, Hata et al. 1996; 
Heldin, Miyazono et al. 1997; Derynck and Zhang 2003; Schmierer and 
Hill 2007; McDowall, Edwards et al. 2008). Activins have only been shown 
to lead to phosphoryltation of smad2 and smad3, whereas stimulation 
with BMPs resulted in phosphorylted smad1, smad5 and smad8 (Harrison, 
Wiater et al. 2004).   
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Figure 1. 9 General mechanism of smad dependent TGF-ß signalling 
pathway. The ligand binds transmembrane receptor serine/threonine 
kinases (types I and II) and type-II receptor kinases activate the 
type-I receptor. Activated Type-I receptors phosphorylate R-smads, 
which then form a complex with smad4 and translocate into the 
nucleus, where they regulate transcription of target genes 
(Schmierer and Hill 2007). 
 
In addition to smad-dependend signaling, activins can activate also other 
signaling cascades such as p38 MAPK, Erk and JNK kinase pathways 
(Derynck and Zhang 2003). Activation with rapid kinetics in some cases 
results from smad-independend signaling, whereas the slow activation 
(>15min) suggests dependence from transcription (Massague 2000). 
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1.2.5. Biological Function of Activin 
 
The biological activity of activins on cell growth and differentiation are 
basically mediated through the smad-dependent signalling pathways. 
Hep3B cells treated with activin A showed growth inhibition by 
downregulating Bcl-xL (anti-apoptotic) expression through smad2 or 
smad3 (Kanamaru, Yasuda et al. 2002). Besides treatment of HepG2 cells 
with activin induced cell cycle arrest and increased gene expression of the 
cyclin-dependent kinase  inhibitor p15INK4B (Ho, de Guise et al. 2004). It 
has been demonstrated that activin is overexpressed in wounded skin and 
the overexpression of activin in the epidermis of transgenic mice helps 
wound healing and enhances scar formation (Munz, Smola et al. 1999; 
Chen, Wang et al. 2006). Inhibition of activin activities delays wound 
healing in the skin but improves the quality of the healed wound (Chen, 
Wang et al. 2006). In addition to the regulation of cell growth, activin 
plays a key role in morphogenesis and regulation of branching organs 
such as the prostate, lung, and kidney (Ball and Risbridger 2001) and it 
regulates the differentiation of human trophoblast tissues during early 
pregnancy (Caniggia, Lye et al. 1997). 
 
Activin A induces apoptosis in numerous types of cells and tissues. In 
hematopoietic cells, activin/TGF-β induced expression of SHIP (SH2 
domain-containing inositol phosphatase). This phosphotase is a regulator 
of phospholipid metabolism and mediates changes in the pool of 
intracellular phospholipids, downregulation of Akt/PKB phosphorylation 
and cell survival (Valderrama-Carvajal, Cocolakis et al. 2002).  In 
addition, activin-C and activin-E have also been demonstrated to induce 
apoptosis in either human or rat hepatoma cells (Vejda, Erlach et al. 
2003). 
 
In addition to effecting apoptosis, activin may have other anti-tumorigenic 
functions. The proliferation of human tumor cells derived from gall bladder 
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(Yokomuro, Tsuji et al. 2000) , prostate (McPherson, Mellor et al. 1999), 
and pituitary gland (Danila, Inder et al. 2000) is decreased by activin. 
Activin inhibits the proliferation of T47D breast cancer cells by 
upregulating of p15 cyclin-dependent kinase inhibitors and 
phosphorylating the retinoblastoma protein (Burdette, Jeruss et al. 2005). 
In this respect, biological function of activin seems to be similar to the 
TGF-β effect on epithelial cells. Besides. activin A also indicates its tumor 
suppressor function as an inhibitor of angiogenesis (Chen, Wang et al. 
2006).  
 
Finally, to find out the complicated biological functions of activin in cell 
proliferation, differentiation as well as in carcinogenesis is not simple. For 
instance, activin can be tumorgenic or antitumorigenic as described 
above, depending on the setting (Chen, Wang et al. 2006). Increased 
expression levels of activin A in human endometrial adenocarcinoma 
tissues have been proposed to be involved in carcinogenesis, by reducing 
activin mediated signals which have inhibitory effect on these tissues 
(Tanaka, Toujima et al. 2004; Chen, Wang et al. 2006). In addition, 
activin A has been demonstrated to lead to high expression of N-cadherin 
on the carcinoma cell surface that is associated with tumor aggressiveness 
(Yoshinaga, Inoue et al. 2004).  
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1.3. Activin Binding Proteins 
 
1.3.1. Activin Antagonist Structures 
 
The actions of activin are cell type specific. In some tissues or cell types, it 
induces proliferation, whereas in others it causes differentiation or 
apoptosis (Stove, Vanrobaeys et al. 2004). In addition, both 
overexpression as well as inhibition of activin signaling is correlated with 
multiple pathological states, including reproductive disorders, 
inflammation and carcinogenesis (Risbridger, Schmitt et al. 2001; Chen, 
Lui et al. 2002; Cho, Yao et al. 2003). Negative regulation of activin 
signaling may occur by mutation or downregulation of activin response 
genes or inhibitory interaction at the level of smad family members (Chen, 
Lui et al. 2002). In addition, several activin binding proteins such as 
follistatin, cripto, and FLRG regulate the activity of activin and block its 
interaction with activin receptors (Gumienny and Padgett 2002; Gray, 
Harrison et al. 2003).  
 
Fst was first purified from ovarian follicular fluid and identified as a follicle 
stimulating hormone suppressing substance (Esch, Shimasaki et al. 1987; 
Robertson, Klein et al. 1987). It has been demonstrated that alternative 
splicing events at the 3`end of the mRNA cause production of different 
isoforms, which undergo post-translational proteolytic processing (Sugino, 
Sugino et al. 1997; Patel 1998). The most common isoforms of follistatin 
are Fst-315 and Fst-288. Fst-288 has a higher affinity for heparin sulfated 
proteoglycans located on the cell surface. This helps Fst-288 to be 
concentrated on the cell surface and create a barrier that prevents activin 
from accessing its transmembrane receptors (Delbaere, Sidis et al. 1999; 
Xia and Schneyer 2009) and leads to endocytosis and degradation of 
surface bound activin (Hashimoto, Nakamura et al. 1997). Fst-315 
encodes an additional acidic C-terminal tail that interferes to some extent 
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with heparin binding. Therefore Fst-315 is the major isoform in solution 
(Schneyer, Hall et al. 1996). Both  isoforms contain an N-Terminal activin 
binding and three sequential 10-cysteine follistatin domains, the first one 
(Wang, Keutmann et al. 2000) contains a lysine rich heparin binding 
sequence (Wang, Keutmann et al. 2000; Sidis, Schneyer et al. 2001; Innis 
and Hyvonen 2003).  
 
Follistatin-like-1 (Fstl1) is a 308 amino acid extracellular glycoprotein. It 
has been grouped into the follistatin family but has only limited functional 
and structural similarity to Fst. It was first cloned from a mouse 
osteoblastic cell line as a TGF-β inducible gene (Shibanuma, Mashimo et 
al. 1993; Hayette, Gadoux et al. 1998).  
 
Follistatin related gene (FLRG) encodes an extracellular matrix protein 
that has been also referred to as Fst-like-3 (Fstl3) (Schneyer, Tortoriello 
et al. 2001). The overall structure of FLRG is quite similar to Fst and the 
domains such as the N-terminus, the follistatin domains and the tail 
domain are each encoded on separated exons. FLRG has one follistatin 
domain less than Fst and does not contain a heparin binding sequence 
(Schneyer, Tortoriello et al. 2001).  
 
Another activin-antagonistic protein, cripto is a 36 kD protein containing 
two cysteine rich domains, an epidermal growth factor-like domain that 
takes part in Nodal signaling, and a CFC (cripto-FRL-criptic) domain that 
binds ALK4. Cripto makes complexes with activin A in the presence of 
ActRII/IIB receptor and so reduces activin A cross linking to ALK4 (Gray, 
Harrison et al. 2003; Strizzi, Bianco et al. 2005; Kelber, Shani et al. 
2008). 
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1.3.2. Interaction between Follistatin and Activin  
 
The mature follistatin protein described above consists of an N-terminal 
unique domain, called Fs0 and three follistatin domains Fs1, Fs2 and Fs3. 
(Shimasaki et al, 1989; Ullman and Perkins, 1997). 
 
The activin A–Fs1 and Fs2 complex structure was shown to have a 1:2 
stoichiometry with binding of follistatin to the outside surfaces of the 
activin subunits. The flexibility of the domain structure of follistatin allows 
it to bend and follow the curvature of the activin subunits (Figure 1.10) 
(Harrington, Morris-Triggs et al. 2006). 
 
The dimeric structure of activin A has been shown to be in a more closed 
conformation in comparison to BMPs and TGF-βs, with the follistatins 
binding from the side in the complex (Figure 1.10B) (Harrington, Morris-
Triggs et al. 2006). Each follistatin fragment in the structure interacts with 
only one of the activin subunits via its Kazal-like subdomain, while the 
heparan sulphate binding EGF-like N-terminal part points away from 
activin, and is poorly resolved in the structure. On the other hand, the Fs2 
domain interacts with activin using both EGF- and Kazal-like subdomains 
with different orientation (Hohenester, Maurer et al. 1997; Harrington, 
Morris-Triggs et al. 2006)  
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Figure 1. 10 Model of activin–Fs1-2 complex. (A) Binding of two follistatin fragments 
to the back of the activin A fingers. Activin protomers are painted red and orange, 
the interchain disulphide is coloured in yellow. Follistatin domains Fs1 and Fs2 are 
shown in blue and green, respectively. (B) Model of the closed conformation of 
activin and Fs1-2 fragments wrapping along activin A. (Modified from EMBO 
Journal,(Harrington, Morris-Triggs et al. 2006). 
 
 
1.3.3. Regulation of Activin Activity by Antagonists 
 
It has been shown that follistatin plays a significant role in the regulation 
of various actions of activin. The interactions between follistatin and 
activin can be occurring by two mechanisms; (i) follistatin binds 
circulating activin thereby preventing activation of its receptors (Figure 
1.11), (ii) follistatin bound by heparin sulfate at the cell surface forms a 
complex with activin causing its endocytosis and lysosomal degradation 
(Figure 1.11) (McDowall, Edwards et al. 2008).  
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Figure 1. 11 Mechanisms of activin antagonism 
by follistatin. Follistatin either binds activin in 
the circulation or it attaches to heparin sulfate 
proteoglycans on the cell surface and captures 
activin there.  (Modified from The Journal of 
Biological chemistry, Nakamura, Assosiation of 
Follistatin on Cell Surface, s19436, 1991) 
 
 
These two hypotheses were tested by producing different isoforms of 
recombinant follistatin and FLRG studying their binding kinetics for various 
TGF-β ligands as well as their capability to block biological activity when 
transfected into cells or when added as proteins. The Fst isoforms and 
FLRG possess comparable activin binding kinetics but their cell surface 
binding significantly differed (Sidis, Mukherjee et al. 2006). Surprisingly, 
the degree of inhibition of endogenous activin bioactivity depended on 
surface binding activity, whereas inhibition of exogenous activin activity 
was not markedly different among the Fst isoforms (Sidis, Mukherjee et al. 
2006). This supports the hypothesis that memrane localization via heparin 
sulfate proteoglycans markedly increases the inhibition of autocrine activin 
(Xia and Schneyer 2009).  
In support of the hypothesis, that follistatin isoforms show different actions 
in vivo, cDNAs of two isoform were expressed transgenically under the 
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control of the human Fst promoter and crossed into the Fst null mouse line 
(Xia and Schneyer 2009) that had been reported to be neonatally lethal 
(Matzuk, Lu et al. 1995). The Fst-288 protein expressing transgenic mice 
did not rescue this lethality, whereas Fst-315 expression allowed mice to 
survive with an - albeit partial - reversal of the skeletal abnormalities seen 
in Fst null mice (Lin, Craythorn et al. 2008).  Nevertheless, these mice 
showed neonatal growth retardation, decreased tail growth and female 
infertility. These results suggest that the shorter Fst-288 isoform may be 
necessary for ovarian function and normal vascularization. On the other 
hand, the Fst-315 isoform is sufficient for other regulatory systems that 
when absent or deficient, result in neonatal death (Lin, Craythorn et al. 
2008).   
 
FLRG does not contain a heparin binding sequence and thus does not bind 
cell surface proteoglycans (Sidis, Mukherjee et al. 2006). When comparing 
its secretion with that of the Fst isoforms using 35S pulse-chase labeling, 
FLRG was found to be secreted slowest with a fraction of newly 
synthesized proteins being transported to the nucleus, whereas Fst-288 
was secreted faster and Fst-315 was secreted and synthesized fastest 
(Saito, Sidis et al. 2005). Interestingly, the nuclear FLRG protein was 
glycosylated but not to the same degree as secreted FLRG, suggesting it 
may be acquired from the endoplasmic reticulum resident pool that means 
it is transported directly to the nucleus without being secreted (Saito, 
Sidis et al. 2005). These results suggest that FLRG and Fst may have 
extracellular as well as intracellular roles that are governed to some 
degree by heparin binding affinity (Saito, Sidis et al. 2005; Xia and 
Schneyer 2009).  
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1.4. Aims of the study 
 
 
Previous data from the literature demonstrate that Fst is frequently 
overexpressed in melanoma cells (Stove, Vanrobaeys et al. 2004). 
Unpublished observations from our group suggested, however, that 
melanoma cells can be growth inhibited by treatment with exogenous 
activin A. The aim of this study was therefore to further investigate the 
role of activin signals in melanoma growth and progression. 
 
In the first part of the thesis the objective was to analyse the expression 
of activins and their functional antagonists in a panel of melanoma cell 
lines established from primary melanoma or metastatic lesions in 
comparison to primary melanocytes. 
 
The goal of the second part of the thesis was to engineer melanoma cells 
to stably overexpress Fst-315. These sublines were then characterized 
with respect to proliferation, migration and tumor growth by various in 
vitro assays as well as in a xenotransplant model in vivo. 
 
The third aim of this thesis was to establish the impact of the activin beta 
E subunit on activin A-mediated signaling mechanisms.  
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2. Materials and Methods 
 
2.1. Cell lines and Media 
 
All melanoma cell lines (Table 2.1) were supplied by the cell culture 
department of the Institute of Cancer Research. Roswell Park Memorial 
Institute (RPMI) medium with 10% fetal bovine serum (FBS) was used for 
all melanoma cell lines. RPMI medium and FBS were purchased from 
Sigma Aldrich. Penecilin/Streptomycin was bought from PAA and added to 
the medium only for selection of stable transfectants. 
 
Table 2. 1 Used cell lines. PT: Primary tumor; MT: Metastases; SC: Subcutaneous; LM: 
Lymph node; BN: Bone; BR: Brain; ME: Malignant effusions; SMM: Superficially 
spreading melanoma; NM: Nodular Melanoma; PM: Primary Melanocytes. 
Melanoma Cell Lines 
VM  No. Cell Line Origin Histology 
VM-7  GTBS PT NM 
VM-10  JMUM PT SSM 
VM-21  RHTP PT NM 
VM-23  RKTJ PT NM 
VM-30  WCRE PT SSM 
VM-1 FTSL/A LN SSM 
VM-8 GUBS/A LN NM 
VM-24 STHJ/A LN Unknown 
VM-28 TMFI BR Unknown 
VM-47 HOST BR NM 
VM-48 KAKA BR NM 
VM-31 WLTJ ME NM 
Other Cell Lines 
HepG2 Human hepatoma cell line (Knowles, Howe et al. 1980)  
MGC Human glioblastoma cell line (Allerstorfer, Sonvilla et al. 2008)  
HEK293 Cell line derived from human embryo renal cortical cells (Graham, 
Smiley et al. 1977) 
 
 
 
 
 
 
 
 
    39 
Table 2. 2 Used Media in cell culture.  
DMEM Dulbecco's modified Eagle's medium for Hek293 cells with 10% FBS; 1% P/S 
RPMI Roswell Park Memorial Institute 
medium 
for all melanoma cell lines with 10% FBS; 
1% P/S 
MNP MEME; 1 mM sodium pyruvate 
(Sigma); 1% non-essential amino acids 
(PAA) 
for HepG2 and MGC cells with 10% FBS; 
1% P/S 
 
 
2.2. Standard Growth Conditions 
 
All melanoma cell lines were grown in a humidified incubator (Forma 
Scientific) at 37°C and 5% CO2. Tissue culture flasks (T25 (=25cm
2), T75 
(=75cm2) and T175 (=175cm 2)) were bought from Greiner Bio-One as 
well as from BD Falcon. 6-well, 12-well and 24-well plates were bought 
from IWAKI. 15 cm tissue culture dishes were bought from Sarstedt and 
96-well-plates were from TPP.  
 
2.3. Splitting 
 
To split the adherent cells, medium was aspirated and cells were washed 
once with PBS (2.7 mM EDTA (Merck); 137 mM NaCl (Merck) and 10 mM 
Na2HPO4 (Merck) pH 7.4). Trypsin/EDTA (T/E; 0.01% EDTA (Fluka); 0.1% 
Trypsin (Difco)) was added and incubated at 37°C for about 5 minutes 
depending on the cell line. Cells were resuspended in medium and the 
desired number of cells was seeded into a new dish or tissue culture flask, 
containing full medium. 
 
2.4. Cell Counting 
 
Cells were counted by using either a Casy Cell Counter (Schärfe) or a 
Neubauer Chamber (Phelan, 2007; Paul Marienfeld GmbH). 
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2.5. Freezing  
 
Cells were grown in T75 culture flask in full medium until they were nearly 
confluent, were trypsinized with tyrypsin (T/E) and resuspended in 5 ml 
medium with 10% FBS. 1 ml of cell suspension was transferred into cryo 
tubes (Greiner) and 50 µg/ml DMSO (dimethylsulfoxid) were added. The 
suspension was immediately put on ice and cooled down in a styrofoam 
container at –80°C for at least 24 hours. Afterwards, cells were 
transferred into a liquid nitrogen tank for long term storage. 
 
2.6. Miniprep 
 
Plasmid minipreps were performed by the Wizard Plus SV Miniprep DNA 
Purification System (Promega). 50 ml of bacterial over night culture were 
pelleted, centrifugation was done at 15 000 g for 1 min. Supernatant was 
removed and cells were solubilized by 250 µl Cell Resuspension Solution, 
then 250 µl Cell Lysis Solution were added and the reaction was incubated 
for 3 min at RT. 10 µl Alkaline Protease Solution were pipetted into the 
solution and incubated again for 5 min at RT. This step was followed by 
the adding of 350 µl Neutralization Solution and centrifugation at 16 100 g 
for 10 min. Supernatant was transferred to a Spin Column which had been 
inserted into a Collection Tube and centrifuged for 1 min at 16 100 g. 
Flowthrough was removed and 750 µl Column Wash Solution were added 
to the column. Centrifugation was done at 16 100 g for 1 min and 
flowthrough was removed again and another 250 µl of fresh 
Wash Solution were added to the column and passed through by another 
step of centrifugation for 2 min. 50 µL of nucleuase free water were added 
to the column and DNA was eluted by a final centrifugation step at 16 100 
g for 1 min into an Eppendorf tube.  
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2.7. Lipofection 
 
3 x 105 cells were seeded into 6-well plates with 2 ml 10% FBS containing 
appropriate medium and incubated overnight. Next day, cells achieved 
about 50-80% confluence. Either FuGENE 6 (Roche) or Turbofect 
(Fermantas) was used as lipofection reagent. 97 µl Serum Free Medium 
(SFM) were transferred into Eppendorf tubes, 3 µl transfection reagent 
were added directly into the medium, mixed in a total volume of 100 µl 
and incubated for 5 minutes. Then 1 µg plasmid was added, mixed and 
incubated for another 25 minutes at room temperature. If the plasmid did 
not contain a desired selection marker, a second plasmid possessing the 
specific marker was added, thereby performing a co-transfection.  
The total volume of transfection suspension was dropped onto the medium 
containing adherent cells and gently shaken (2 ml/well of a 6-well plate). 
The following day, lipofected cells were expanded into 10 cm tissue 
culture dishes, thereby medium was changed, and incubated overnight. 
Then the standard growth medium was changed to selection medium 
containing antibiotics, according to the used resistance gene. 
 
2.8. Selection of Stable Transfectants 
 
As antibiotics neomycin/G418 or puromycin were used to select for cells 
that had integrated the plasmid coding for a selection marker and the 
gene of interest into their genome. To reduce the fake clone phenomenon, 
where only selection markers integrate into the genome but not the gene 
of interest, some plasmids coded for bicistronic mRNAs with gene of 
interest and selection marker seperated only by an IRES (Internal 
Ribosomal Entry Site) sequence (Gurtu, Yan et al. 1996).  
During post-transfection, either G418 or puromycin was added to the cells 
and selection medium was changed several times to remove the dead 
cells.  When resistent clones appeared, usually after 1-2 weeks, clones 
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were picked and reseeded to facilitate growth. New cell lines were frozen 
down and tested for expression, as soon as possible, to reduce the risk of 
losing clones due to contamination. However, all selection media 
contained also penicillin and streptomycin to prevent bacterial infections. 
All generated cell lines were tested for expression of the respective genes 
of interest by Western Blot analysis, ELISA and qRT-PCR.  
 
Table 2. 3 Stable transfectants and their selection 
Gene of interest Vectors Selection 
Activin-A pHs INHBA-IRESpuro Puromycin 
Follistatin-315 pFst315/EGFPe  Neomycin 
Follistatin-288 pFst288/EGFPe  Neomycin 
Follistatin-like-1 pHsFstl-1-IRESpuro Puromycin 
FLRG pIRESpuro-Fstl-3 Puromycin 
Control GFP EGFP-IRESpuro Puromycin 
Control GFP EGFP-IRESneo  Neomycin 
Control GFP   pLuc-IRESe-EGFPneo  Neomycin 
 
2.9. Microscopy 
 
All microscopy methods (Light, fluorescence and fluorescence time-lapse 
microscopy) were performed using an Eclipse TE300 microscope (Nikon), 
a Digital Sight DS-5M (Nikon) or SPOT INSIGHT (Diagnostic Instruments) 
CCD camera and MetaMorph software (Molecular Devices). All microscopy 
was performed at room temperature. 
 
2.10. Isolation of RNA   
 
Cells were grown in T25 cell culture flasks. When they were almost 
completely confluent, medium was discarded and cells were washed with 
cold PBS (2.7 mM EDTA (Merck), 137 mM NaCl (Merck) and 10 mM 
Na2HPO4 (Merck); pH 7.4). Following steps were performed on ice. Trizol 
(Invitrogen) was added onto the cell layer (for 25cm2 confluent cell layer 
1.5 ml volume was used). The cells were scraped in Trizol reagent and 
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were transferred into 2 ml Eppendorf tubes. Lysating cells were vortexed 
and incubated for about 5 minutes. For RNA extraction, 
chlorophorm/isomylalcohol (50:1; 0.2 x vol. Trizol) was added, vortexed 
and incubated again for approximately 5 min. Cell waste was centrifuged 
down at 11 000 g at 4°C for 10 min. Aqueous supernatant, containing 
resuspended RNA was transferred into new Eppendorf tubes and 
isopropanol (0.5 times vol. Trizol) was added, vortexed and again 
centrifuged at 11 000 g at 4°C for 10 min. Supernatant was discarded and 
about 0.5 ml of 70% EtOH/DEPC  was added onto the pellet, vortexed and 
centrifuged at 7 500 g at 4°C for 7 min. The alcohol was removed, the 
pellet was air dried and taken up in DEPC/EDTA (3 mM; 10-30 µl volume) 
water. As quality control, purified RNA was loaded onto agarose gel (1 µg 
RNA; 1% agarose gel) and separated. RNA was frozen at –20°C or at –
80°C for long term storage.  
 
2.11. Determination of RNA Concentration 
 
The concentration of purified RNA was determined by a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
 
 
2.12. cDNA Syntesis for qRT-PCR 
 
Total RNA was extracted from approximately 5 x 105 cells and 1 µg RNA 
was diluted with DEPC water to 11 µl and incubated for denaturation at 
70°C for 10min. Afterward it was put on ice. Final volume was brought to 
20 µl by addition of 9 µl cDNA Synthesis Master Mix (Table 2.4). Then it 
was incubated for 1.5 hours at 37°C. The quality of cDNA was tested by 
performing standard RT-PCR of a “housekeeping gene” and agarose gel 
electrophoresis. cDNA was stored frozen at –20°C. 
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Table 2. 4 cDNA synthesis master mix 
Stock for 1X; 20µl 
RNA (1µg in 11µl DEPC water) 11µl 
M-MLV RT buffer (5X; Promega) 4µl 
dNTPs(10mM) 1µl 
DTT( 100mM) 2µl 
Hexanucleotids (20ng/µl) 1µl 
MMLV-RT (200 u/µl; Promega) 1µl 
  20µl total volume 
 
 
2.13. Reverse Transcriptase PCR 
 
The RT-PCR Master Mix was prepared on ice. 1 µl cDNA solution was 
pipetted into 0.2 ml PCR Tube Strips (Bio-Rad) and then the Master Mix 
was added and mixed. Reaction was carried out in a MyCyclerTM Thermal 
Cycler (Bio-Rad). For PCR conditions and primer sequence see tables 2.5 – 
2.7 below. 
 
Table 2. 5 General reaction mixes for RT-PCR 
17.375 µL nuclease free water (Fermentas) 
5 µL 5X Colorless GoTaq Reaction Buffer 
(Promega) 
0.5 µL dNTPs (10mM; Fermentas) 
0.5 µL upstream primer (20 µM) 
0.5 µL downstream primer (20 µM) 
0.125 µL GoTaq DNA polymerase (5 units / µL) 
1 µL template DNA 
 
 
Table 2. 6 Primer used for RT-PCR 
Target cDNA Sense primer (5´-3`) Antisense primer (5`-3`) 
  
Follistatin Ccagcgagtgtgccatgaag tcatcttcctcctcttcctcg 
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Table 2. 7 RT-PCR Conditions 
Gene of Interest Dissociation Annealing Elongation 
Follistatin    
Temperature (°C) 94 61 72 
    
Number of Cycles Time  
1x 3´     
35x 30´´ 50´´ 50´´ 
1x     2 
 
 
 
2.14. Quantitative Real Time-PCR (qRT-PCR)-Taqman 
 
The TaqMan Master Mix was prepared on ice. 2 µl of serial 10-fold 
dilutions of original cDNA template were layered into two wells (per 
sample) of 96-Well Reaction Plates (Micro AmpR; Applied Biosystems), in 
case of 18S-rRNA for normalization. 10 µl Master Mix was added to a total 
volume of 12 µl. Fluorescence was measured using an ABI Prism 7000 
SDS fluorometer (ABI), according to ABI manuals. Following amplification, 
CT values, ∆CT values and Log2 ratios were recorded for target genes and 
internal standards. 
 
Table 2. 8 Real time PCR master mix 
Reagent Volume  
(for 1 sample) 
Taqman universal PCR mix 6.25µl 
Probe 0.625µl 
cDNA 2.00µl 
H2O 3.125µl 
  12µl total volume 
 
 
2.15. Restriction Digest 
 
Master Mix, including restriction enzyme and corresponding buffer 
(Fermentas), was prepared on ice. 15 µl of the PCR product was 
resuspended with 5 µl Master Mix and so digestion was performed in a 
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total volume of 20 µl. Incubation time was usually 60 min at the 
suggested incubation temperature (usually 37°C), unless different 
conditions were required for the enzyme as suggested by Fermentas. 
 
Table 2. 9 Reagents of restriction digest 
Master Mix 
1µl Restriction 
Enzyme 
  2µl Buffer 
  2µl Water Mix 
Restriction 
Digestion 15µl PCR Product 
  5µl Master mix 
 20µl (Tot.Vol.) 
 
 
2.16. Gel Electrophoresis  
 
DNA and RNA fragments were seperated on gels consisting of 0.5-1% 
(w/v) agarose (Bioenzyme) in 0.5 x TBE buffer (5.4 g/l Tris (Fluka), 2.75 
g/l boric acid (Sigma) and 1 mM EDTA). Samples were mixed with 6 x 
loading buffer (333 µl/ml 6 x loading dye (Fermentas), 250 µl/ml 80% 
glycerol (Merck), 66.5 µl/ml 0.5 M EDTA, 0.5 µl/ml 10 000 x Vistra Green 
(GE Healthcare)) and loaded onto the gel. Depending on expected 
fragment sizes 2 µL GeneRuler 1 kb DNA Ladder or 100 bp DNA Ladder 
(Fermentas) markers mixed with appropriate amounts of water and 
loading buffer were used. As running buffer for agarose gels 0.5 x TBE 
was used and the run was initiated with constant voltage of 50 V for 10 
min followed by 120 V until the marker dye indicated sufficient separation. 
The gel was stopped and bands were visualized using a 
FluorImager 595 Scanner from Molecular Dynamics.  
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2.17 Precipitation of Protein from Cell Supernatants and 
Preparation for Gel Electrophoresis 
Serum free cell supernatant was transferred to a SS34 centrifugation tube 
and 4 volumes of 100% EtOH were added. The solution containing cell 
supernatant and 100% EtOH was incubated at –20°C overnight. The 
following day precipitate was harvested by centrifugation at 4°C for 
10 min at 15 000 g. Supernatant was removed and the precipitate was 
washed in cold 70% EtOH. It was pelleted again at 16 100 g for 5 min. 
Supernatant was removed completely and the pellet was briefly left to 
dry. It was then resolubilized in a minimal volume (typically 25 µl for the 
precipitate from a T25 bottle) of sample buffer (7.5 M urea (Merck); 
1.5 M thiourea (Sigma); 4% CHAPS (Merck); 0.05% SDS (Fluka)). 
Insoluble precipitate was removed by centrifugation at 16 100 g for 5 min. 
Finally 6 µl 5 x SDS-PAGE loading buffer  were added and the mixture was 
loaded onto the gel without prior heating to prevent carbamylation of the 
proteins in the sample (McCarthy, Hopwood et al. 2003). 
 
2.18. Isolation of Proteins from Cells  
 
To isolate protein from cells for SDS-PAGE and Western blot analysis, 
around 5 x 105  cells were seeded  in a 6-well and incubated overnight. 
The next day, growth medium was removed and cells were firstly washed 
two times with cold PBS and then were scraped (Cornig) into PBS. Cells 
were pelleted by centrifugation at 1 000 g for 2 min. All successive steps 
were done on ice. Supernatant was removed and pellet was lysed by 
adding 2 x Laemmlie buffer (4% SDS; 24% glycerol; 120 mM 
Tris/HCl pH 6.8; 2,8% 2-mercaptoethanol (Aldrich); 0.01% bromophenol 
blue (Koch-Light Laboratories))and sonification 3 x for 3 sec (Bandelin). 
Amounts of protein were analyzed by SDS-PAGE.  
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2.19. Polyacrylamide Gel Electrophoresis and Western 
Blot 
 
For detection of a protein of interest in cell lysate or supernatant, samples 
were separated by SDS-PAGE (Gallagher 2007) and immunoblotted. The 
Mini Protean 3 system (Bio-Rad) was used for blotting and transfer of 
protein to a PVDF membrane (Hypond-P; GE Healthcare) for 
immunodetection with specific antibodies. Denaturing, discontinous 
polyacrylamide gels with gel densities of the separation between 10 and 
15% were typically used. Occasionally PAGEr Gold Precast Gels 4-20% 
(Lonza) were used. The separation gel was cast and topped with 
isopropanol. Following polymerization (15-30 min), isopropanol was rinsed 
off with water which was removed with filter paper. The stacking gel was 
then cast on top of the separating gel. Prior to loading, the gel pockets 
were cleaned with SDS running buffer (25 mM tris; 
192 mM glycine; 0.1% SDS) which was also used as running buffer for all 
SDS-PAGE gels. For each pocket 5-25 µg of protein lysate were mixed 
with 5 x SDS-PAGE loading buffer and heated for 5 min to 95°C before 
being loaded. 5 µL of Page Ruler Plus Prestained Protein Ladder 
(Fermentas) were used as a marker. The gel was run at a voltage of 60 V 
for 30 min, followed by 120 V until the the bromphenol blue tracking dye 
had left the gel. 
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Table 2. 10 Preparing of PAGE gels 
 Seperation gel 10% 15% Stacking gel  
ml Water 1960 1122 Water 1.5 
ml 1.6 M Tris pH 8.8 1250 1250 0.5 M Tris pH 6.8 0.625 
µL 10% SDS 100 100 10% SDS 25 
ml 30% Acrylamid/Bis; 
29:1 (Bio-Rad) 
1675 2513 30% Acrylamid/Bis; 
29:1 
325 
µl 10% APS (Merck) 25 25 APS 25 
µl TEMED (Amresco) 5 5 TEMED 2.5 
 
 
For Western blotting, separated proteins were transferred to a PVDF 
membrane using the tank transfer system (Gallagher, Winston et al. 
2008). Before assembly of the blotting sandwich, the PVDF membrane 
was activated with methanol, rinsed thoroughly with tap water and 
equilibrated in Towbin buffer (25 mM Tris; 192 mM Glycin; 5% MeOH) 
which was also used as transfer buffer. Transfer was performed at a 
current of 200 mA for 2 h at 4°C with a –20°C cooling pack in the tank. 
Following transfer, the membrane was rinsed with distilled water and 
protein bands were visualized using Ponceau S staining. The membrane 
was incubated with Ponceau S solution (0.5 g/L Ponceau S (Sigma); 
1 ml/l glacial acetic acid (Gallagher, Winston et al. 2008) for 5 min. 
Background staining was removed by washing several times with distilled 
water. Staining was documented using a photocopier. 
Following incubation, membranes were blocked with TBST-M (TBS: 
8 g/L NaCl; 0.2 g/L KCl; 3 g/L tris; pH 7.4; T: 0.1% tween 20 (Sigma); M: 
5% skim milk powder (Fluka)) for 1 h on a shaker at RT. Membranes were 
then washed 3 x 5 min and incubated in primary antibody solution over 
night in a 15 ml Falcon tube on a shaker at 4°C. See Table 2.11 for 
antibodies used. The next day, membranes were washed 3 x with TBST 
and incubated in secondary antibody solution for 1 h on a shaker at RT. 
This was followed by washing 3 x with TBST and 2 x with TBS before 
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incubation upside-down on a parafilm with Immun-Star WesternC reagent 
(Bio-Rad) and visualization of the signal with Hyperfilm ECL (GE 
Healthcare). 
 
Table 2. 11 Antibodies used for western blot 
Antibody Dilution Supplier diluent 
size of 
target 
Mouse-anti-GFP 1:2000 Roche; 11814460001 TBST-M 27kDa 
Rabbit-anti-Phospho-smad2 1:1000 Cell Signaling; 3101 TBST-M 60kDa 
Rabbit-anti-smad2/3 
1:1000 
Cell Signaling; 3102 TBST-
5%BSA 60kDa 
 
 
2.20. Smad Phosphorylation Assay 
 
HepG2 cells were seeded and incubated in full medium overnight. Medium 
of HepG2 cells was removed and cells were washed 2 x with PBS. 1 ml of 
conditioned media from transfected HEK293 cells or purified recombinant 
cytokines were added, and the cells were incubated for 30 min in the 
incubator. Cells were then harvested as described under 2.18 and cell 
lysates were subjected to gel electrophoresis and western blot. 
 
 
2.21. ELISA 
 
The Quantikine Elisa kit was used for the quantitative determination of 
human follistatin concentrations in cell culture supernatants. A suggested 
10-fold dilution of 25 µl cell culture supernatants were mixed with 225 µl 
Calibrator Diluent RD5-21. Standards for calibration were used according 
to the manufacturer's instructions (16.000 pg/ml-4000 pg/ml-1000 pg/ml-
250 pg/ml). After 100 µl of Assay Diluent RD1-8 were added to each well, 
100 µl of control, sample and standard were also added and the wells 
were coverd with the adhesive strip provided. They were incubated for 3 h 
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at 4° C. A plate layout is provided to record standards and samples 
assayed. Each well was aspirated and washed, the process was repeated 
three times for a total of four washes. After the last wash, remaining 
Wash Buffer was removed by decanting. The plate was inverted and 
blotted   against clean paper towels. 200 µl of cold follistatin conjugate 
were added to each well and they were coverd with a new adhesive strip 
and incubated for 2 h at 4°C. Wash and aspiration steps were performed 
as described before. Afterward 200 µl of Substrate Solution were added to 
each well and protected from light. They were incubated 20 min at RT. By 
adding of 50 µl Stop Solution the colour in the wells changed from blue to 
yellow. The optical density of each well was measured at 450 nm and 
correction was set to 540 nm or 570 nm using a Synergy spectrometer. 
 
2.22. Growth Curve Assay 
 
Cell lines stably transfected with the desired construct were counted under 
the microscopy and then seeded to 12-well plates at a density of 1x105 
cells/well. Number of viable cells was measured every second day until the 
eighth day, using the Casy Cell Counter. 
 
2.23. Clonogenic Assay 
 
Cells were washed with PBS, trypsinized and counted. 100 and 1000 cells 
were seeded into six well plates containing 2 ml RPMI medium (10% FCS) 
to form colonies in 1–3 weeks. After the desired clone sizes (>1 mm) 
were reached, depending on specific clonogenicity of the cell line used, 
cells were stained with crystal violet. Numbers of clones larger then 1mm 
in diameter were counted.  
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2.24. Crystal Violet Staining 
 
Supernatant of cells was removed, cells were washed (PBS) and fixed by 
incubation in Methanol:Aceton (1:1) for about 20 minutes. Then fixation 
solution was changed to crystal violet solution, diluted 1:1000 in PBS 
(stock: crystal violet in PBS and 10% ethanol) and incubated for another 
20 minutes. Staining solution was discarded and cells were air dried over 
night. 
 
 
2.25. Soft Agar Assay 
 
For the anchorage independent growth assay, the bottom agar layer 
consisted of soft agar medium and 1% agar solution. Soft agar medium 
(2ml NaHCO3 (110 mg/ml, in water bidest.), 1 ml glutamin, 17 ml water 
(bidest.) and 50 µl folic acid in 10 ml 10 x RPMI medium (Sigma)) was 
prepared the day before seeding of the cells. The solution was brought to 
a pH value of 8 and filtered. Afterwards, 20 ml FCS and 1ml penecilin-
streptomycin were. To form the bottom layer, the solution was brought to 
a temperature of 37-40°C. For the 1% agar solution, 1.2 g agar was 
added to 80 ml water (bidest.) and solubilized by cooking. Simultaneously 
another 30 ml of water (bidest.) were cooked up and used to fill up the 80 
ml suspension to 100 ml and finally kept at 40°C in the water bath.  
 
The next day, 30.000 cells were pelleted at 800 rpm for 5 min and gently 
resuspended in 750 µl soft agar medium, pre-warmed to 37°C. The 750 µl 
1% agar solution, which was kept at 41°C in the water bath was added to 
the cell suspension and mixed 1:1. The total volume of 1.5 ml was added 
on top of the bottom agar layer and gently shaken, thus resulting in a 
total volume of 3 ml per well of a six well plate. Clone size was quantified 
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using metamorph software and after the desired clone size was reached 
(>30 µm), the number of clones was counted under the microscope.   
 
 
2.26. MTT Assay 
 
For determination of cell viability, the MTT kit EZ4U from Biomedica was 
used according to the manufacturer’s protocol. Approximately  2000 
stably transfected cells were seeded in 100 µl  4% and 10% serum  
containing RPMI medium into each well of a 96 well-plate. After five days 
incubation, 20 µl of MTT tetrazolium salt solution were added in each well 
and incubated for 2-3 h at 37°C. Absorption was measured at 450 nm and 
620 nm as reference using a Synergy spectrometer.  
 
2.27. Transwell Migration Assay 
 
For investigating cell migration, transwell chambers of 24 well-plate 
format were used. 40 000 sample and untreated control cells in 200 µl 
medium were seeded into porous chambers, 800 µl medium were pipetted 
into the well, resulting in a total volume of 1 ml. RPMI medium containing 
4% and 10% FCS was used. Migration through porous chambers was 
visualized by crystal violet staining. Incubation times ranged from 24-72 
hours.  
 
 
2.28. Tumor Growth in SCID Mice 
 
For xenotransplantation experiments, cells were seeded in 10% RPMI and 
incubated, until they were nearly confluent. Afterwards cells were counted 
by Casy. A final number of 1.2x107 cells was pelleted and resuspended in 
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300 µl serum free RPMI medium (for 4 mice). All successive steps were 
done on ice. 1.5x106 cells per mouse were injected subcutaneously. 
Tumor growth was checked every two to three days by palpation and 
measured with a calliper. Tumor volume was calculated according to the 
formula: shorter diameter2 x longer diameter x 0.5. All animal 
experiments followed FELASA guidelines and were approved by the local 
ethics committee. 
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3. Results 
 
3.1. Expression Analysis of Activin Family Members and 
Activin-Antagonizing Proteins in Melanoma Cell Models 
by Real-Time PCR 
 
To verify the potential involvement of activin signals in melanoma, we 
have investigated the expression of all four human activin subunits and 
antagonistic factors, such as follistatins and cripto, in a panel of human 
melanoma cell lines (Figure 3.1, 3.2.). 
 
 
Figure 3. 1 Expression levels of activin subunits beta A, B, C and E in melanoma cell 
models established from primary tumors (PT) or metastatic lesions from lymph nodes (LN) 
or brain (BR) or from malignant effusions (ME). Each bar represents relative expression of 
the individual cell lines compared to primary melanocytes (PM). All detectable Ct-values 
were normalized to 18S-rRNA expression.  Primary melanocytes were used as calibrator 
(set as 1). Fold expression values were calculated using the formula: 2^(-ddCT) and 
results were Log2 transformed.  
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Expression levels were investigated by real-time PCR in 12 human 
melanoma cell lines and normal melanocytes (PM).The activin subunits 
beta A, beta B, beta C and beta E were detectable in all cell lines. Elevated 
expression levels of activin beta C (10/12) were found in melanoma cell 
lines, compared to primary melanocytes. The expression of activin beta B 
(9/12) and activin beta E (11/12) in contrast, was clearly downregulated, 
whereas activin beta A showed up- or down-regulation depending on the 
cell line. Overall activin beta A had the lowest Ct values (range 25 – 35) 
corresponding to highest expression levels, whereas activin beta C was 
least expressed with most CT values above 35 (Figure 3.2). 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3. 2 The scatter plots show the 
expression levels of activin subunits in 
the melanoma cell lines. Values are 
given as cycle threshold numbers (Ct 
values). Each dot represents the mean 
of two determinations. 
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Activin antagonists were also detectable in all cell lines. Expression levels 
of follistatin (9/12) and cripto (12/12) showed mostly upregulation 
compared to primary melanocytes. On the other hand follistatin-like-1 and 
FLRG were up- or down-regulated, depending on the cell line (Figure 3.3). 
The lowest CT values (highest expression) were found for follistatin-like-1 
(Figure 3.4).  
 
Figure 3. 3 The expression patterns of the activin-antagonizing proteins were determined 
by real-time PCR. Each bar represents the log2 transformed fold expression value 
compared to PM. PM: Primary Melanocytes; PT: Primary Tumor; LN: Lymph Node 
Metastases; BR: Brain Metastases; ME: Malignant Effusions. 
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Figure 3. 4 Cycle threshold values plotted 
for follistatin, follistatin like-1, FLRG and 
cripto as means of duplicate samples. 
 
 
 
 
3.2. Determination of Follistatin Isoform Expression by 
RT-PCR  
 
Follistatin is produced by all melanomas according to quantitative 
expression analysis (Figure 3.3.). As follistatin can be expressed as two 
different isoforms termed Fst-315 and Fst-288, we tested, which isoform 
is predominantly expressed in melanoma models. Only one of the two 
isoforms of follistatin, encoding a 27 amino acid extention at the C-
terminus, Fst-315 was found in nearly all melanoma cells, including 
primary melanocytes (Figure 3.5). Therefore, it appears that Fst-288 is 
not produced by most melanoma cells.  
 
 
 
Fs
t
Fs
t li
ke
 
1
FL
RG
Cr
ipt
o
20
25
30
35
40
Ct
 
v
al
u
es
    59 
 
Figure 3. 5  RT-PCR analysis of Fst-315 and Fst-288 cDNA in the indicated cells. 
The long isoform-Fst315 (corresponding to the 115bp PCR fragment) is detectable 
in all cell lines, whereas the short form of follistatin (379bp) is produced at a 
significant level only in VM48 cells. 
 
 
 
3.3. Generation of Stable Cell Lines  
 
For further analysis of the role of activin family members or activin 
antagonists in melanoma, we focused on cell models with low endogenous 
expression levels to generate stable cell lines, which overexpress various 
activin or activin antagonizing proteins.  
 
VM1, VM48 and VM21 cells were transfected with expression vectors 
coding for various variants of different activins and follistatins. As 
described in the materials and methods section, melanoma cells were 
transfected using FuGene 6 transfection reagent with plasmids expressing 
besides the gene of interest also GFP and/or a selection marker. Stable 
transfectants were successfully selected for resistance to G418 or 
puromycin antibiotic drugs. See table 3.1 for a list of stable cell lines, 
generated during this diploma thesis. Expression levels of stable cell lines 
transgenic for Fst were functionally verified by Western Blot analysis and 
by ELISA.  
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Table 3. 1 List of the generated stably transfected cell lines 
Cell line 
 
Plasmid used for 
transfection 
Gene of interest to be overexpressed 
and function 
VM48* pfst315/EGFPe Follistatin isoform 315 
VM48 pfst288/EGFPe Follistatin isoform 288 
VM48 pIRESpuro-fstl-3 FLRG 
VM48 pHsINHBA-IRESpuro Activin A 
VM48 EGFP-IRESpuro EGFP/control 
VM48 pEGFP-IRESneo3 EGFP/control 
VM48* pLuc-IRESe-EGFPneo GFP-Luciferase/control 
VM21* pfst315/EGFPe Follistatin isoform 315 
VM21* pLuc-IRESe-EGFPneo GFP-Luciferase/control 
VM21* EGFP-IRESpuro EGFP/control 
VM1* pfst315/EGFPe Follistatin isoform 315 
VM1* pLuc-IRESe-EGFPneo GFP-Luciferase/control 
VM1* EGFP-IRESpuro EGFP/control 
 
 
Cells, labeled with (*) in the table, were checked by FACS (Fluorescence 
Activated Cell Sorter) analysis for accurate quantification of fluorescent 
cells. The ell lines ectopically expressing follistatin 315 and respective GFP 
controls were then used for further characterization and investigations. 
 
 
 
3.4. Confirmation of Overexpression of Follistatin in 
Follistatin Transfected Melanoma Cell Lines with 
Different Methods. 
 
3.4.1 Smad Phosphorylation Western Blot 
 
The Western blot is a reliable method used to detect specific proteins. 
Follistatin and GFP overexpressing melanoma cell lines were cultured for 
two days and supernatants were collected. HepG2 cells were treated with 
supernatants of these cells mixed with 5 ng/ml recombinant activin A and 
incubated for 30 minutes, in order to verify whether follistatin-315 
transfected melanoma cells produce sufficient follistatin protein to inhibit 
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activin-mediated smad2 phosphorylation. Untreated HepG2 cells and 
HepG2 cells which were treated with 5ng/ml recombinant activin A or 
5ng/ml recombinant activin A + 20ng/ml recombinant follistatin were used 
as positive and negative controls. Cells were harvested, lysed by adding 
Laemmli buffer and separated using SDS-PAGE gel. Western blotting was 
done using an anti-phospho-smad2 antibody and a total smad2/3 
antibody as loading control.  
 
When 5 ng activin A was added to the medium, smad2 phosphorylation 
was decreased in all melanoma cell lines overexpressing follistatin 
compared to those overexpressing GFP (Figure 3.6), implying that 
follistatin blocks activin activity. Of note, although stimulation using 
recombinant activin and follistatin reduces smad phosphorylation only 
about 20%, ectopically expressed follistatin can inhibit up to 75%. This 
means that the generated follistatin expressing melanoma cell lines 
contain enough follistatin to block activin activity. Follistatin expressing 
VM48 cell supernatants, however, inhibit smad phosphorylation to a much 
lesser degree than those from the other other two follistatin 
overexpressing cell lines.  
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Figure 3. 6 Inhibition of activin A-induced smad signaling by 
follistatin overexpression. Cell lysates of HepG2 which had been 
incubated with supernatants of the indicated melanoma cells + 5 
ng/ml recombinant activin A , were analysed using an anti-phospho-
smad2 antibody (A) and a total smad2/3 antibody (B) and signal 
intensity quantified by ChemiCapt and Bio1D software (C). 
Smad2/smad2/3 ratios were calculate and those derived from the 
respective GFP control supernatans were set as 100%.  
 
 
3.4.2. Analysis of Follistatin Overexpression by ELISA 
 
Before analysing the influence of follistatin overexpression on cell 
proliferation, differentiation, or migration in melanoma cell lines, we first 
determined the amount of follistatin secreted by the cells, into the culture 
media by immunoassay. 
 
ELISA is an effective method for quantitative determination of human 
follistatin concentration in cell culture supernatants from serum free media 
containing secreted follistatin proteins. The assay was performed 
according to the Quantikine-Human Follistatin Immunoassay protocol. 
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This immunoassay is calibrated with recombinant human follistatin, and 
detects all isoforms of follistatin. All melanoma cells were grown to about 
80% confluence in serum containing medium in 6 well plates, prior to 48h 
incubation in serum free medium, which was then harvested and used for 
the analysis. For standard curve generation, recombinant human follistatin 
proteins were added to RPMI media at a concentration ranging from 250 
pg/ml to 16.000 pg/ml.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 7  Expression of follistatin was confirmed 
and quantified by detecting follistatin in the 
supernatant of transfected VM1, VM21 and VM48 
cells by ELISA using different concentrations of 
human recombinant follistatin protein as 
standard.  
 
 
In all cases, except follistatin transfected VM48 cells, overproduction of 
follistatin compared to GFP controls was confirmed. Supernatants of 
follistatin transfected VM21 cells contained approximately 120 ng/ml 
follistatin, and those of VM1 cells even 250 ng/ml (Figure 3.7).  
 
Together with the smad2 Western analysis, these results show that 
follistatin transfected cells secrete enough follistatin to regulate activin 
activity via the smad signaling pathway.  
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3.5. Functional Analysis of Follistatin Overexpressing 
Melanoma Cells 
3.5.1. Cell Proliferation / MTT Assay 
 
In order to test the impact of follistatin on cell proliferation, follistatin 
overexpressing VM1, VM21, and VM48 cells and their respective GFP 
containing controls were seeded into 96-well plates at low densities. After 
5 days, cell number was measured by MTT assay using staining and 
spectroscopic methods as described under 2.24. 
 
The results clearly show that follistatin overexpression has a different 
effect on cell proliferation depending on the cell lines (Figure 3.8). 
Apparently, follistatin mediated blocking of activin bioactivity leads to a 
decreased MTT-reducing activity of about 60% in VM21 cells, compared to 
the GFP control. In VM48-Fst cells proliferation was decreased also by 
around 20% compared to VM48-GFP when cells were grown in medium 
with 4% FCS, despite the low ectopic expression level of follistatin 
according to the ELISA analysis. On the other hand proliferative activitiy of 
VM1 cells, which expressed a high level of ectopic follistatin, was not 
reduced. Additionally, we observed that the effect of follistatin on 
proliferation capability was significantly influenced by adding different 
concentration of FCS to the cell culture media. In medium with 10% FCS 
neither VM1-Fst nor VM48-Fst cells showed any difference in growth 
compared to GFP controls, whereas the growth reduction of VM21-Fst cells 
was even more pronounced.  
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Figure 3. 8 Cell proliferative activity of 
follistatin overexpressing melanoma cells 
by MTT assay. Melanoma cells stably 
transfected with follistatin or GFP (as 
control) were incubated in medium with 
4% (A) as well as  10% (B) FCS for five 
days. Two independent experiments were 
performed in duplicates for three different 
VM cell lines.  
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3.5.2. Growth Curve Assay  
 
Next, growth curves of the follistatin overexpressing cell lines were 
determined. Cell lines, which were stable transfected with follistatin and 
GFP constructs, were seeded at low density and cell numbers were 
measured every two days until the eighth day, using a Casy Cell Counter 
(Figure 3.9). In agreement with the proliferation assay (3.8.), cell VM21-
Fst showed also a reduced growth, whereas no significant differences 
between follistatin and GFP transfected cells was seen in VM1 and VM48 
cells.  
 
 
 
Figure 3. 9 Growth curve assay for three VM cell lines. Cells were incubated in 
10% FCS containing medium. Viable cell number was measured every two 
days after seeding until the eighth day using a Casy Cell Counter.  
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3.5.3. Clonogenic Assay 
 
Clonogenic assays were performed to investigate the role of overexpresed 
follistatin in colony formation ability of human melanoma cells. Follistatin 
transfected cells were seeded at densities resulting in formation of visible 
colonies within 1–3 weeks. Colonies were fixed with methanol and stained 
with crystal violet (1%). They were quantified manually under a 
microscope (Figure 3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 10 Effect of follistatin overexpression on 
colony formation. (A) Number of clones in follistatin 
transfected cells (compared to GFP controls) (B) 
Representative examples.  
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The results showed that overexpression of follistatin caused a significant 
inhibition of number and size of surviving colonies from the VM21 cell line 
when compared with GFP transfected control cells, whereas VM1 and 
VM48 cells showed a clearly increased colony formation compared with the 
controls.  
 
 
3.5.4. Soft Agar Assay 
 
To test whether follistatin influences the ability of melanoma cell lines to 
grow in soft agar and become anchorage independent VM1-Fst and VM21-
FST cells and respective GFP controls were seeded in 10% RPMI medium 
containing agar. They were incubated for four weeks and observed for 
colony formation. Quantification was performed by counting the number of 
clones with a clone size >30µm (Figure 3.11 and 3.12).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 11 Soft agar colony formation for 
follistatin expressing VM1 and VM21 cells. Bars 
show the averages of the two independent wells. 
GFP expressing controls for each melanoma cell 
line were used as reference and set as 100% 
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Results indicated that anchorage independent growth was reduced by 
about 45% in follistatin overexpressing VM21 cells compared to GFP 
expressing VM21 cells, whereas anchorage-independent growth in VM1 
cells was not different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 12 Examples of melanoma cell clones 
growing in soft agar. Follistatin and GFP expressing 
melanoma cells were plated into soft agar and 
resulting colonies counted after four weeks. The 
number of colonies was counted at four different areas 
per well.  
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3.5.5. Migration Assay 
 
Transwell assays were used to investigate, whether overexpression of 
follistatin and accordingly activin blocking in melanoma cells affects their 
migration potential.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 13 In vitro migration of follistatin-expressing melanoma cells. 
Cell migration was measured using transwell chamber migration 
assays. 40000 cells were seeded into a transwell chamber in media 
containing 4% FCS or 10% FCS and incubate for 72 hours. Cells which 
migrated through the porous membrane to the bottom surface of the 
membrane were stained with crystal violet and staining was quantified 
by Lucia Software Representative examples of two independent 
experiments done in duplicates. 
 
In the transwell migration assay, cells in medium containing 4% and 10% 
serum were added to the upper chamber and allowed to migrate through 
a porous filter. Filters were stained with crystal violet and then cells, which 
had not migrated through the filter, were scratched off the upper surface, 
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to detect only those cells that had migrated to the lower surface (Figure 
3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 14 Quantification of transwell assay 
results. Cells were seeded and stained as 
described in figure 3. 13. Bars represent two 
independent sets of experiments.  
 
VM1 and VM21 melanoma cell lines showed a generally lower migratory 
activity compared to VM48. In all three cell lines tested, the follistatin 
expressing cells had a reduced migratory activity compared to the 
respective GFP controls, suggesting that activin signaling may be 
necessary for cell migration. Additionally, cell migration ability was similar, 
when the cells were grown in 4% or 10% FCS.  
4% FCS
VM
21
-
Fs
t
VM
1-F
st
VM
48
-
Fs
t
0
20
40
60
80
Control
10% FCS
VM
21
-
Fs
t
VM
1-F
st
VM
48
-
Fs
t
0
20
40
60
80
Control
    72 
3.5.6. Tumor Growth in a SCID Mouse Model 
 
Finally, the ability of follistatin-transfected versus GFP-transfected VM21 
cells to establish tumors in SCID mice were investigated. The clones of 
follistatin-expressing VM21 cells as well as GFP-transfected VM21 cells 
were injected subcutaneously into SCID mice (4 per group). All mice 
injected with VM21 cells developed tumors. However, there was no 
obvious difference in tumor growth between VM21-GFP and VM21-Fst cells 
with respect to tumor volume. Mice with VM21-GFP tumors seemed to 
survive a little bit longer than those with tumors from VM21-Fst cells 
(Figure 3.15, 3.16). Upon dissection of the mice it was noted that two of 
the VM21-GFP tumors had developed metastatic lesions adjacent to the 
main tumor and in the lymph nodes. The tumors as well as lungs, brains, 
livers, and bones (femurs) of the mice were fixed in formalin and 
embedded in paraffin for further analysis in subsequent projects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 15 Percent survival of SCID mice bearing tumors 
from follistatin-expressing and GFP-expressing VM21 cells. 
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Figure 3. 16 VM21 cells (3x106 in 50 µl PBS) were injected subcutaneously 
into SCID mice. The tumor size was measured in two dimensions (a,b) and 
the tumor volume (mm3) was calculated by using the formula: V=(a2xb)/2; 
b>a. Mice were sacrificed when the tumor volume reached a size of about 
5000 mm3. 
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3.6. Impact of the Activin Beta E Subunit on Signal 
Transduction via the Smad Pathway 
 
The signaling mechanisms of activin E (as homodimer of two beta E 
subunits) or of heterodimeric activins containing a beta E subunit are 
currently unknown. To elucidate the impact of the beta E subunit on signal 
transduction via smad2, 293 cells (which have a very high transient 
transfection rate) were transfected with various combinations of cDNAs 
leading to expression of activin beta E, activin beta A, activin antagonists 
and yellow or cyan fluorescent protein (YFP, CFP). Then we treated 
hepatoma cells (HepG2) with these conditioned media and analyzed 
smad2 phosphorylation by Western blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 17 Efect of conditioned media from 293 cells 
transfected with activin beta A, activin beta E, follistatin-
315 and YFP on smad signaling in HepG2 cells. Bars 
represent the ratios of the psmad2/smad2/3 signals. 
Unstimulated HepG2 cells (control) were set as 1. 
Ponceau staining is shown as additional loading control. 
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Activin A-conditioned medium induced smad2 phosphorylation in HepG2 
cells, whereas the activin E-conditioned medium had no effect (Figure 
3.17). Follistatin binds to activin A with high affinity and blocks interaction 
of activin receptor with its ligand (Nakamura, Takio et al. 1990). In 
consequence, conditioned media from 293 cells co-transfected with activin 
beta A and follistatin did not lead to smad2 phosphorylation confirming 
that follistatin blocks specifically the activity of activin A but not activin E 
in HepG2 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 18 Stimulation of smad2 phosphoryation by 
treatment with activin A-conditioned medium in VM 48 
cells and effect of different inhibitors. Activin can be 
blocked by follistatins, but not by cripto. Fold control 
was calculated using the formula: (psmad2)/(smad2/3) 
and untreated controls were set as 1. 
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Activins interact with various binding proteins, which include antagonists 
in the extracellular space (follistatin and FLRG) and antagonistic co-
receptors at the cell membrane (cripto). Deregulation of activin signals 
has been found in several tumor types and linked to the malignant growth 
of tumor cells (Deli, Kreidl et al. 2008). Follistatin is an important and 
critical regulator of activin in many adult tissues, including melanoma. 
Compared to follistatin, less information is available about the biological 
activity and physiological actions of follistatin-like-1, cripto and FLRG. To 
test the ability of different antagonists to inhibit activin signals in 
melanoma cell lines, VM48 cells, which expressed only low levels of activin 
antagonists (see Figure 3.1.), were treated with conditioned media from 
293 cells co-transfected with cDNAs coding for acitivn beta A and different 
activin antagonists.  
Our observations indicated that follistatin can block activin-induced smad2 
phosphorylation approximately 2 times more efficiently than FLRG or fstl-
1, whereas cripto was unable to block smad2 phosphorylation (Figure 
3.18).   
 
Next, it was tested, whether co-transfection of activins beta E and A could 
alter the smad2 phosphorylating activity of conditioned media, and 
whether the additional presence of follistatin would influence the result 
(Figure 3.19) 
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Figure 3. 19 In HepG2 cells, both isoforms of 
Follistatin (288 and 315) are effective in blocking 
activin A signals. Expression of the beta E subunit 
seems to slightly enhance stimulation by activin beta 
A, but does not influence blocking of activin signals 
by follistatin. Untreated control was set as 1. 
 
 
Results indicate that activin beta A and E co-transefected conditioned 
medium caused significant induction of phosphorylated smad2 similar to 
conditioned medium from cells transfected with beta A alone. Co-
transfection with follistatin (either the 288 or 315 isoform) in all cases 
abrogated smad2 phosphorylation. The results suggest that activin beta E 
does not interfere with activin A signaling directly or indirectly via 
follistatin.  
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Figure 3. 20 Transcript expression of activin beta A, activin beta E and follistatin in 293 
cells after transfection with the indicated transgenes. Delta CT values were calculated by 
subtracting the CT values of 18S ribosomal RNA from the CT values of the respective 
analysed gene.  Transfections: (A) activin beta A and control vector YFP in co-transfected 
Hek293 cells; (B) activin beta E and control vector YFP in co-transfected Hek293 cells; 
(C) activin beta A, activin beta E and control vector YFP in triple-transfected Hek293 
cells; (D) activin beta A, activin beta E and follistatin in triple-transfected Hek293 cells. 
(E) Endogenous expression levels of targeted molecules in YFP transfected and in (F) 
untransfected 293 cells.  
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To verify in 293 cells overexpression of the different transgenes, which 
were used to produce the conditioned media described above, RNA was 
isolated from 293 cells 48 hours after transfection, reverse transcribed 
and expression levels of activin beta A, beta E, and follistatin were 
determined with Taqman assays.  The 18S ribosomal RNA was used as 
reference and delta CT values were determined. Gene expression level 
and delta CT values have an inverse correlation, because lower CT value 
reflects increased gene expression, in other words, a high efficiency of 
transgene expression. These results revealed that both of activin subunits 
and follistatin were easily detectable and that ectopic expression resulted 
in a specific decrease of the CT value for the respective transcript of at 
least 10 cycles compared to the endogenous expression, corresponding to 
1000-fold overexpression (Figure 3.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 21 Influence of different ratios of activin beta 
A and beta E cDNAs on smad2 phosphorylating activity 
of conditioned media. Conditioned media were 
generated and smad2 phosphorylation determined in 
HepG2 cells as described above. Bars represent 
psmad2/total smad2/3 ratios. 
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Finally, it was investigated whether the beta E subunit might influence 
activin A-induced smad2 phosphorylation when expressed in excess of 
activin beta A, as is the situation in normal hepatocytes. For that purpose, 
we prepared conditioned media from 293 cells after co-transfection of 
activin beta A and activin beta at different ratios (1:1 activin beta A + 
activin beta E; 1:6 activin beta A + activin beta E; 1:8 activin beta A + 
activin beta E) and treated HepG2 cells as above. Results indicate that 
conditioned media from 293 cells transfected with activin beta A (500 ng 
plasmid DNA) induced smad2 phosphorylation independent of the amount 
of co-transfected activin beta E plasmid.  
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4. Discussion 
 
4.1. Expression Analysis of Activins and Follistatins  
 
Activins have been found involved in the control of many cellular 
processes, ranging from the control of hemeostasis to cell growth, 
differentiation and tissue patterning during embryogenesis in multiple 
adult tissues (Ball and Risbridger 2001; Luisi, Florio et al. 2001; Chen, Lui 
et al. 2002; Stove, Vanrobaeys et al. 2004). A previous study has 
indicated that follistatin is highly expressed in the majority of melanoma 
cell lines (Stove, Vanrobaeys et al. 2004). The present study has 
demonstrated that all melanoma cell lines investigated expressed activin 
subunits and activin antagonistic proteins and showed smad 
phosphorylation upon treatment with activin. Activin beta A was up- or 
downregulated depending on the melanoma cell line, whereas activin beta 
C was upregulated in the majority of cell lines in our panel compared to 
primary melanocytes. With respect to signal transduction and function, 
however, activin beta C has also been described as inhibitor of activin A 
(Butler, Gold et al. 2005; Gold, Jetly et al. 2009). In contrast, activin E 
and activin B were demonstrated to be mostly downregulated compared to 
primary melanocytes. Downregulation of activin A has also been observed 
in high-grade breast cancer and transient upregulation of activin E in 
rodent liver after partial hepatectomy or portal vein branch ligation 
(Huang, Li et al. 2002; Jeruss, Sturgis et al. 2003; Takamura, Tsuchida et 
al. 2005).  
 
Since activin A signals have a pro-apoptotic and growth inhibitory function 
in many cell types it has been suggested that cancer cells may escape 
from the effects of activin by several alternative ways; by downregulation 
or mutation of activin responsive genes or by alterations interfering with 
the activin signaling pathway (Chen, Lui et al. 2002). Alternatively, 
several factors such as follistatin, inhibin or cripto inhibit the ability of 
activin to gain access to its receptor (Gumienny and Padgett 2002; Stove, 
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Vanrobaeys et al. 2004). In our investigation, follistatin and cripto were 
upregulated in the majority of melanoma cell lines compared to primary 
melanocytes, whereas no clear trend towards up- or down-regulation was 
seen for FLRG and follistatin-like-1. As previously reported, follistatin is 
expressed in most of the organs, which also express activin related 
proteins (Michel, Rao et al. 1991; Tuuri, Eramaa et al. 1994) and  the 
highest expression of follistatin was found in testis, ovary and pituitary 
(Tortoriello, Sidis et al. 2001). However, in some animal models including 
human liver cancer expression of follistatin levels was increased in about 
60% of tumor tissues (Grusch, Drucker et al. 2006). Whereas the highest 
tissue expression of FLRG was found in placenta (Tsuchida, Arai et al. 
2000; Tortoriello, Sidis et al. 2001), in contrast to follistatin, FLRG is 
expressed at high level in normal liver but downregulated in human liver 
tumors. In accordance with this finding, the data from this thesis suggest 
that malignant melanoma cells and primary melanocytes follow a similar 
pattern as liver tumor cells and normal liver cells with respect to follistatin 
and FLRG expression.  Overall it appears that the balance of activins to 
activin antagonists is shifted towards the antagonist side in melanoma 
cells compared to primary melanocytes.  
 
 
4.2. Effect of Overexpression of Follistatin on Melanoma 
Cells 
  
As most of the melanoma cell lines showed high expression levels of 
follistatin, the consequences of high follistatin levels for the malignant 
behavior of melanoma cells was investigated.  For that purpose three 
different cell lines, two of them (VM21 and VM48) with low endogenous 
expression) were stably transfected with follistatin and subjected to 
various growth assays. We could demonstrate that stable transfection with 
follistatin clearly decreased the number of cells compared with GFP control 
in VM21 cells. This effect was investigated using two different detection 
methods in three different cell lines (VM1, VM21 and VM48). The 
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metabolic activity of cells (MTT assay) and cell number were determined. 
Stove et al. showed that exogenous activin is able to decrease 
proliferation and induce apoptosis in primary melanocytes (Stove, 
Vanrobaeys et al. 2004). Consequently, we speculated that ectopic 
expression of follistatin might lead to increased proliferation via blockade 
of endogenously produced activin A, especially in melanoma cells with low 
endogenous follistatin expression. However, while melanoma cells 
ectopically overexpressing follistatin showed decreased smad2 
phosphorylation when stimulated with exogenous activin A, none of them 
had a growth advantage and VM21 even showed reduced proliferation. A 
similar decrease compared to GFP controls was found for VM21 cells also 
with respect to colony formation, migration in transwell assays, and 
anchorage-independent growth in soft agar. VM1 and VM48 cells showed 
increased colony formation but decreased migration. While high 
expression of endogenous antagonists like cripto could account for lack of 
response to follistatin overexpression, the growth inhibitory effect of 
follistatin could either mean that activin signals may be growth 
stimulatory for melanoma cells as has been reported for several tumor 
types like esophageal carcinoma (Yoshinaga, Yamashita et al. 2008), or 
lung cancer (Seder, Hartojo et al. 2009) or that follistatin acts via 
induction or inhibition of some other genes involved in cell cycle 
regulation. The importance of aberrant cell cycle regulation by signaling 
pathways in melanoma has previously been highlighted by the observation 
that almost 70% of melanomas and primary nevi have kinase-activating 
mutations in BRAF (Davies, Bignell et al. 2002; Pollock, Harper et al. 
2003; Goodall, Wellbrock et al. 2004). Furthermore activating mutations 
in BRAF inducing activation of MAP kinase signaling pathway are key 
characteristics of melanoma (Davies, Bignell et al. 2002). This constitutive 
activation of the MAP kinase cascade might switch activin signals from 
growth inhibitory to growth promoting and these pro-tumorigenic 
activities of activin signals might be antagonized by follistatin.  
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In summary, overexpression of follistatin in human malignant melanoma 
could decrease their proliferation via two different signaling pathways, 
blocking of the activation of smad family of transcription factors and 
interference with TGF-β family receptor-mediated crosstalk with the 
BRAF/MAP kinase dependent signaling intracellular pathway (Grusch, Petz 
et al. 2010).  
 
It has been shown that melanoma invasion requires migration through the 
vascular barrier and is necessary for the adhesion of metastatic cells to 
the endothelium (Teti, De Giorgi et al. 1997). Results of the migration 
assays indicate that cell migration levels were reduced, when activin which 
shares the intracellular signaling pathway with TGF-β was blocked by 
overexpressed follistatin. This suggests that activin-mediated smad 
signaling may be necessary for cell migration and activin could be one of 
the genes involved in the coordinated expression changes associated with 
migration. 
 
As known, follistatin can regulate also potentially tumor growth. Krneta et. 
al. demonstrated that activin-expressing mammary carcinomas grow 
faster than follistatin-expressing tumors, which grow slower than activin-
transduced or mock-transduced tumors (Krneta, Kroll et al. 2006). 
Additionally, follistatin transfectants of small cell lung cancer cells induced 
fewer metastatic colonies in multiple organs, when compared with their 
control clones (Ogino, Yano et al. 2008). Deregulation in the activin 
signalling pathway may also result in disturbances of normal bone 
metabolism and has been implicated in bone metastasis in prostate cancer 
(Leto 2010). 
 
In this thesis, VM21 cells overexpressing follistatin showed no difference 
compared to GFP controls with respect to tumor volume in a SCID mouse 
xenotransplant model. However, follistatin expressing tumors did not lead 
to metastasis compared with control tumors. During dissection of the 
mice, metastatic lesions were observed in the lymph nodes of the triangle 
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of the neck in two of four mice bearing VM21-GFP cells but not in mice 
bearing VM21-Fst cells. Tumors and several organs including lungs and 
bones of the mice have been fixed and paraffin embedded and will be 
analysed for the presence of metastases in future work.  
 
 
 
 
4.3. Understanding the Signalling Pathway of Activin E  
 
Members of the TGF-β superfamily execute their biological activities by 
binding serin-threonine kinase receptors followed by phosphorylation of 
smad proteins. The first branch of the smad signaling pathway uses 
smad2 and smad3 and is shared by TGF-β activin and nodal, the second 
branch of the signaling pathway uses smad1, smad5 and smad 8 and is 
shared by BMPs and GDFs (Ethier and Findlay 2001). To elucidate whether 
activin E could activate smad2 signaling, a plasmid expressing activin beta 
E was transiently transfected into 293 cells and supernatants were 
collected and used for treatment of HepG2 cells. A plasmid expressing 
activin beta A was used as positive control. Treatment of HepG2 with 
activin E conditioned media showed no smad2 signal. Thus our 
investigation of the signaling pathway of activin E suggests that smad2 
can not be activated by activin E. However as no receptors for activin E 
have been identified, it cannot be ruled out at present that failure to 
activate smad2 is caused by the lack of expression of a suitable 
combination of receptors for activin E in HepG2 cells.  
 
As mentioned in section 3.1. follistatin is an activin binding protein and 
antagonizes the binding activity of activin A to its receptor, forming an 
inactive complex (Nakamura, Takio et al. 1990; de Winter, ten Dijke et al. 
1996). It has been previously demonstrated that the endocytotic 
internalization of activin A was accelerated by follistatin into pituitary cells 
leading to lysosomal activin degradation. Activin E can also bind to 
follistatin (Hashimoto, Tsuchida et al. 2002). Therefore we hypothesized 
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that activin E could sequester follistatin into a complex, which could result 
in an increased bioavailability of activin A. However, also according to our 
results even an excess of activin E did not impair the ability of follistatin to 
block activin A-induced smad phosphorylation in HepG2. One reason for 
this could be a much higher affinity of follistatin for activin A than for 
activin E.  
 
According to our western blot results, follistatin blocked the activin A 
binding affinity to its receptor. We observed also that follistatin-like-1 and 
FLRG inhibit activin A activity, albeit with lower efficiency. This is 
surprising for follistatin-like-1 as it contains only one follistatin domain 
and was therefore not expected to bind activins.  
 
To investigate whether activin beta E has an effect on activin A-induced 
smad phosphorylation, we performed co-transfection with present of both 
proteins. It was hypothesized that activin beta E might alter activin signals 
via formation of a heterodimer with the beta A subunit. It was previously 
suggested that activin beta C might form an inactive heterodimer and 
thereby reduce the amount of dimeric activin A, B and AB (Mellor, 
Cranfield et al. 2000; Hashimoto, Tsuchida et al. 2002). In this case the 
activin beta E subunit also could act as an inhibitor of activins. Another 
study showed that activin C as a secreted dimer could inhibit activn A via 
competition for activin receptors (Gold, Jetly et al. 2009). However the 
western blots performed with conditioned media in this thesis seem to 
suggest that transfection of the beta A subunit into 293 cells leads to 
smad2 phosphorylatin activity in conditioned media also when the activin 
beta E subunit is co-transfected at a 1:1 ratio and even at an 8-fold 
increased ratio of beta A over beta E. In addition, follistatin showed its 
antagonizing effect not only in activin A conditioned medium, but also in 
activin A plus E conditioned medium. Taken together, these data argue 
against a major impact of beta E expression on activin A signaling. Thus, 
while these data can disprove some hypotheses, the actual mechansism, 
how the beta E subunit could function, remains enigmatic. 
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5. List of Abbreviations  
Act - Activin 
ActR - Activin Receptor 
ACV - activin receptor 
ALK - Activin Receptor–like Kinase 
APS - Ammonium Persulfate 
BMP - Bone morphogenetic proteins 
BSA - Bovine Serum Albumin 
CDK - Cyclin Dependend Kinase 
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